



Bioactive Molecules for Regenerative Pulp Capping

Journal:	<i>eCM Journal</i>
Manuscript ID	eCM-Sep-2020-DRBSI-0067.R3
Manuscript Type:	Dental Regenerative Biology Special Issue
Date Submitted by the Author:	16-Sep-2021
Complete List of Authors:	Whitehouse, Laura; University of Leeds Faculty of Medicine and Health, Division of Oral Biology, School of Dentistry Thomson, Neil; University of Leeds Faculty of Medicine and Health, Division of Oral Biology, School of Dentistry; University of Leeds Faculty of Engineering, Molecular and Nanoscale Physics Group, School of Physics and Astronomy Do, Thuy; University of Leeds Faculty of Medicine and Health, Division of Oral Biology, School of Dentistry Feichtinger, Georg; University of Leeds Faculty of Medicine and Health, Division of Oral Biology, School of Dentistry
Keywords:	Dental - Regenerative Repair, Dental pulp, Dentine, Signaling molecules / Growth Factors - General , Biomaterials - General, Pulp capping, Dental - Tissues (dentinXXX enamelXXX periodontal ligamentXXX tooth)
Abstract:	<p>Since the discovery of bioactive molecules sequestered in dentine, researchers have been exploring ways to harness their activities for dental regeneration. One specific area, discussed in this review, is the area of dental pulp capping. Dental pulp caps are placed when the dental pulp is exposed due to decay or trauma in an attempt to enhance tertiary dentine deposition. Several materials currently exist for dental pulp capping, however natural biomimetic scaffolds may offer advantages over existing manufactured materials such as improved aesthetics, better biocompatibility and improved success rates. This review discusses and appraises the current evidence surrounding biomimetic dental pulp capping with a focus on bioactive molecules sequestered in dentine and their associated carriers. Molecules covered most extensively in the literature include; the transforming growth factors (TGF-βs, specifically TGF-β1) and bone morphogenetic proteins (BMPs, specifically BMP-2 and BMP-7), with collagen being the most commonly used scaffold material. Further literature exploring synergistic use of multiple peptides needs to be accomplished in tandem with the development of a tailored scaffold carrier. Further illumination on the roles of some of the molecules identified in dentine needs to be explored before they can be considered as potential bioactive molecules in a biomimetic scaffold for dental pulp capping. Future in vivo work needs to consider the inflammatory environment of the dental pulp in pulpal exposures and comparison against current pulp capping materials.</p>


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Table 1: Comparison of primary, secondary and tertiary dentine.

Dentine type	When/Where present
Primary	Produced during initial tooth formation, before the tooth erupts. Produced by odontoblasts.
Secondary	Deposited at a slow rate throughout life after primary dentinogenesis by odontoblasts, reducing the size of the pulp with age. Formed by odontoblasts.
Tertiary	Reactionary: Formed following mild/'slow and chronic' insult to the pulp. Formed by odontoblasts. Tubular structure, similar to primary dentine.
	Reparative: Formed following significant insult to the pulp, resulting in odontoblast death. Formed by odontoblast-like cells derived from resident DPSCs. Atubular structure, often showing some similarities to bone.

ECM For Peer Review



Caption : Figure 1: Schematic diagram summarising the bioactive molecules sequestered in dentine that have been explored in the literature, and this review, for pulp capping dentinogenesis. Molecules with the most evidence supporting their use are in green, amber for intermediate evidence and little evidence in grey. Molecules in grey have been included for completeness. Interactions are shown by arrows. DMP1= Dentine Matrix Protein 1, OPN= Osteopontin, BSP= Bone Sialoprotein, DSPP = Dentine Sialophosphoprotein DSP= Dentine Sialoprotein, DPP= Dentine Phosphoprotein, MEPE= Matrix Extracellular Phosphoglycoprotein, SIBLINGS= Small Integrin-Binding Ligand, N-linked Glycoproteins NGF= Nerve Growth Factor, SCF= Stem Cell Factor, TGF= Transforming Growth Factors BMP= Bone Morphogenetic Proteins, EGF = Epidermal Growth Factor, IGF= Insulin-Like Growth Factor, FGF= Fibroblastic Growth Factor, VEGF= Vascular Endothelial Growth Factor, HGF= Hepatocyte Growth Factor, PDGF= Platelet Derived Growth Factor, PIGF= Placental Growth Factor, GMCSF= Granulocyte Macrophage Colony Stimulating Factor, IgA = Immunoglobulin A, IgG = Immunoglobulin G, IgM = Immunoglobulin M, SLRPS = Small leucine-rich proteoglycans, GDNF = Glial Derived Neurotrophic Factor, BDNF = Brain Derived Neurotrophic Factor, MMP = Matrix Metalloproteinase

296x251mm (300 x 300 DPI)

Bioactive Molecules for Regenerative Pulp Capping

Authors: Whitehouse LLE, Thomson NH, Do T, Feichtinger GA,

Abstract

Since the discovery of bioactive molecules sequestered in dentine, researchers have been exploring ways to harness their activities for dental regeneration. One specific area, discussed in this review, is the area of dental pulp capping. Dental pulp caps are placed when the dental pulp is exposed due to decay or trauma in an attempt to enhance tertiary dentine deposition. Several materials currently exist for dental pulp capping, however natural biomimetic scaffolds may offer advantages over existing manufactured materials such as improved aesthetics, better biocompatibility and improved success rates. This review discusses and appraises the current evidence surrounding biomimetic dental pulp capping with a focus on bioactive molecules sequestered in dentine. Molecules covered most extensively in the literature include; the transforming growth factors (TGF- β s, specifically TGF- β 1) and bone morphogenetic proteins (BMPs, specifically BMP-2 and BMP-7). Further literature exploring synergistic use of multiple peptides needs to be accomplished in tandem with the development of a tailored scaffold carrier. Further illumination on the roles of some of the molecules identified in dentine needs to be explored before they can be considered as potential bioactive molecules in a biomimetic scaffold for dental pulp capping. Future *in vivo* work needs to consider the inflammatory environment of the dental pulp in pulpal exposures and comparison against current pulp capping materials.

Introduction

Caries (dental decay) is the most prevalent non-communicable human disease and is linked to low quality of life (Åkesson et al., 2016). The Global Burden of Disease Study estimated that 3.58 billion people worldwide have untreated caries (World Health Organisation, 2018). Indirect costs (for example, work absence) due to caries worldwide amount to a loss of US\$144 billion/year (Listl et al., 2015), highlighting the significant impact caries has at a global level.

The crowns of teeth are made of enamel, dentine and pulp. Dentine is a living structure, with an inorganic content similar to bone, being predominantly hydroxyapatite, and calcium and phosphate salts (Sloan, 2015). The dental pulp, which is encased by dentine, contains the vessels, nerves and cells that maintain the vitality of the tooth. Dentine and pulp are inextricably linked (termed together 'dentino-pulp-complex' (DPC)). They share embryological origin (both being derived from the ectomesenchyme (Zohrabian et al., 2015)) and both release factors acting on the other (Smith, 2003), facilitating a state of homeostasis and when necessary, regeneration and repair. The DPC is the only part of the tooth with *in vivo* regenerative potential, and is being increasingly studied as a potential for biological scaffold production (Hashemi-Beni et al., 2017; Qu et al., 2015) and dental tissue regeneration.

Dentinogenesis is the production of dentine, and in health this is performed by odontoblasts (dentine producing cells). Odontoblasts are largely inactive after primary dentinogenesis. (Table 1). However, following insult to the pulp, odontoblasts play a role in wound healing in the form of reactionary dentinogenesis, where they lay down dentine to seal the vital pulp from the insult. Should the stimulus be great enough to kill the odontoblasts (such as significant trauma or deep caries), dental pulp stem cells (DPSC) will migrate to the site of injury, differentiate into 'odontoblast-like cells' and begin laying

down dentine, a process called reparative dentinogenesis. This results in a dentine bridge, sealing the precious pulp from further insult (McLachlan et al., 2003).

Table 1: Comparison of primary, secondary and tertiary dentine

Dentine type	When/Where present
Primary	Produced during initial tooth formation, before the tooth erupts. Produced by odontoblasts.
Secondary	Deposited at a slow rate throughout life after primary dentinogenesis by odontoblasts, reducing the size of the pulp with age. Formed by odontoblasts.
Tertiary	Reactionary: Formed following mild/'slow and chronic' insult to the pulp. Formed by odontoblasts. Tubular structure, similar to primary dentine.
	Reparative: Formed following significant insult to the pulp, resulting in odontoblast death. Formed by odontoblast-like cells derived from resident DPSCs. Atubular structure, often showing some similarities to bone.

Tertiary dentinogenesis is driven by dental injury, though the interplay between inflammation and regeneration is a delicate balance. Typically, exposed dental pulps are inflamed and often infected. It is generally accepted that only when infection and inflammation are under control will reparative actions occur in the dental pulp (Cooper et al., 2014). Many of the cytokines and growth factors involved in tertiary dentinogenesis, at high doses, may lead to pulpal death and prevent DPSC differentiation (Cooper et al., 2014). However, certain inflammatory cells (such as macrophages and dendritic cells) have also been shown to stimulate odontoblast differentiation (Goldberg *et al.*, 2008; Saito *et al.*, 2011), and molecules upregulated in caries, such as C5a and stromal cell-derived factor 1/CXCL12 have also been shown to be capable of recruiting immune cells as well as DPSCs (Cooper et al., 2014). These studies highlight the intricate, delicate and vital interplay between inflammation and regeneration in tertiary dentinogenesis and caries.

Reparative dentinogenesis is a complex process, as the DPSCs need to be recruited to the site of injury, undergo differentiation and then begin depositing dentine. Understandably, this is more time-consuming than reactionary dentinogenesis, and because of this it is often ineffective at sealing the pulp from the insult. This process is significantly driven by the release of bioactive molecules (including growth factors, cytokines and other matrix molecules) sequestered within dentine during primary dentinogenesis, and released following dentine damage. These molecules are capable of stimulating reparative and reactionary dentinogenesis (Smith et al., 2012) and summarised in Figure 1.

When a pulp is exposed, through trauma, mechanical action (typically iatrogenic) or caries, the clinician has a choice of whether to attempt to save the pulp (via a direct pulp cap), or not (leading to a root canal treatment (endodontics) or an extraction).

Pulp capping agents (PCAs) attempt to seal the pulp by encouraging tertiary dentine deposition. Direct pulp caps can be technical to perform successfully and correctly, with some studies reporting success rates as low as 9% after pulp exposures at 5 years (Bjørndal et al., 2017). When a pulp is exposed, the tooth needs to be isolated (ideally with a rubber dam), any further caries removed, the area cleaned/wound lavage, haemostasis achieved, the PCA prepared/mixed, placed and allowed to set (if required), and the cavity restored. Clinicians may also decide to remove some of the superficial pulp which has been exposed (termed a 'partial pulpotomy'), in an attempt to remove any inflamed pulpal tissue that may impair healing (Bjørndal et al., 2019). Besides the PCA used, numerous other factors may influence the success rates of a pulp cap, such as; bacterial microleakage from the restoration, operative debris from the cavity preparation, uncontrolled haemorrhage (Murray et al., 2002), the experience of the operator, the type of cavity (interdental/occlusal) (Ritter, 2007), the length of time to permanent

1
2
3 restoration (Mente et al., 2014), the type of exposure (cariou/mechanical/trauma) (Ritter, 2007) and
4 the type of lavage/haemostasis agent used (Tüzüner et al., 2012). A pulp cap is deemed successful if at
5 75-90 days a dentine bridge has formed and the tooth remains vital (Stanley and Pameijer, 1997), though
6 typically a dentine bridge begins to form within 30 days of the original pulp cap and is largely completed
7 by 130 days (Hargreaves and Cohen, 2010). No PCAs currently available are perfect and, considering the
8 prevalence of caries, it is imperative that cost-effective materials with high success rates, desirable
9 clinical outcomes and suitable handling qualities are available for clinical use. Furthermore, the evidence
10 behind the use of many PCAs is generally lacking, with poor quality clinical studies often including; sound
11 teeth, limited follow-up time, lack of histological data, young healthy patients and tooth isolation
12 (Hilton, 2009), which often make comparison to real-life clinical work challenging.

16 Pulp capping Materials

17
18 There are many Pulp capping materials/PCAs available commercially, with $\text{Ca}(\text{OH})_2$, and calcium-silicate
19 based materials (Mineral Trioxide Aggregate (MTA) and other tricalcium silicate based cements) being
20 the most commonly used in practice..

21
22 Of the more commonly used PCAs, $\text{Ca}(\text{OH})_2$ has been used for the longest period of time (having been
23 first explored in the 1920s) and for many years has been considered the 'gold standard' for a direct pulp
24 cap (Hilton, 2009; Qureshi et al., 2014). $\text{Ca}(\text{OH})_2$ is often considered as a bench-mark to compare newer
25 PCAs against – *in vivo* and *in vitro* - and there is a wealth of literature supporting its use. The high
26 alkalinity of $\text{Ca}(\text{OH})_2$ eliminates micro-organisms, providing a favourable environment for
27 dentinogenesis, but this has negative implications too, making $\text{Ca}(\text{OH})_2$ cytotoxic resulting in further
28 pulpal necrosis (Youssef et al., 2019). The exact mode of action for dentinogenesis in a $\text{Ca}(\text{OH})_2$ pulp
29 capped tooth remains contentious, with some people believing the irritation, inflammation and necrosis
30 in the pulp caused by the $\text{Ca}(\text{OH})_2$ initiates dentinogenesis via an unknown pathway, and others
31 suggesting that it is due to $\text{Ca}(\text{OH})_2$ facilitating release of bioactive molecules sequestered in dentine
32 (Bjørndal et al., 2019; Graham et al., 2006; Hilton, 2009), or potentially a mixture of the two. $\text{Ca}(\text{OH})_2$
33 has numerous issues as a PCA, such as; high solubility, lack of adhesion to dentine, and 'tunnel defects'
34 in the reparative dentine formed (Qureshi et al., 2014).

35
36
37 MTA is newer to the commercial market than $\text{Ca}(\text{OH})_2$, though has been used for pulp capping since the
38 1990s (Zafar et al., 2020), and is thought to have better success rates than $\text{Ca}(\text{OH})_2$ according to several
39 systematic reviews (Paula et al., 2018; da Rosa et al., 2018b; Zhu et al., 2015). Moisture is required for
40 MTA to set, and when water is added, a colloidal gel composed of calcium oxide crystals is formed
41 (calcium silicate hydrate) and $\text{Ca}(\text{OH})_2$ is released, imparting much of MTA's known antimicrobial
42 activity (Zafar et al., 2020). MTA is known to liberate numerous growth factors from dentine during
43 pulp capping (Tomson et al., 2017).

44
45
46 Although MTA would appear to be a good PCA based upon the success rates, there are numerous issues
47 with it, for example; long setting times (> 2 hours for some brands), discolouration of teeth, poor
48 handling characteristics (due to its crumbly nature), risk of pulpal obliteration and being expensive
49 (Linsuwanont et al., 2017; Qureshi et al., 2014; Zafar et al., 2020). Due to the release of $\text{Ca}(\text{OH})_2$, MTA
50 also has high alkalinity, which again is cytotoxic (Kim et al., 2019; Youssef et al., 2019). More recent
51 modifications of MTA have attempted to remedy some of these problems (for example, newer
52 generation versions of MTA may have faster setting times, through the addition of calcium sulphate or
53 sodium hypochlorite, the reduction in particle size, or addition of substances to allow for light curing)
54 and reduced tooth discolouration (Zafar et al., 2020), though long term studies demonstrating no
55 reduction in efficacy are lacking.

56
57
58 Newer tricalcium-silicate based cements, (for example, BioDentine™ (Septodont)) have been explored
59 to overcome numerous issues with earlier PCAs (for example, BioDentine™ has a shorter setting time
60 than MTA, and improved handling characteristics (Zafar et al., 2020)), but still problems exist (for

1
2
3 example, tooth discolouration and age-dependent results (Lipski et al., 2018)). Again, due to the high
4 alkalinity of the material, it will have cytotoxic effects on the pulp (Youssef et al., 2019). “No statistically
5 significant differences in the various outcomes” were found in a systematic review when MTA was
6 compared to tricalcium silicate based cements (Paula et al., 2018), though a significant lack of long-term
7 cohort studies and randomised controlled trials were identified as a significant issue, partly due to the
8 newness of the material.
9

10 A lack of a highly effective PCA is the driving motivator behind exploration of more biomimetic
11 approaches to pulp capping, with the hope of discovering and utilising key factors present during
12 tertiary dentinogenesis to drive DPC regeneration. Many of the bioactive molecules within dentine
13 can be liberated by current PCAs (Tomson et al., 2017), or through chemical treatment of the dentine
14 (Zhao et al., 2000), though this release is poorly controlled in terms of frequency and volume. By
15 applying these molecules extraneously, it may be possible to exploit their actions in a biomimetic pulp
16 capping agent to actively drive tertiary dentinogenesis, in a controlled manner, for pulp capping,
17 maintaining the vitality of the tooth. This data can be used to inform dentinogenic scaffold design,
18 allowing for the ideal biomimetic environment to be fabricated that can include the bioactive
19 molecules pertinent for reparative dentinogenesis, and provide an ideal environment for DPSC
20 migration and differentiation, with the exclusion of noxious irritants present in many current PCAs and
21 the inflamed pulp; in essence, harnessing the positive reparative factors of tertiary dentinogenesis
22 and excluding the negative factors that drive pulpal necrosis. Moreover, many of the scaffolds
23 designed to carry bioactive molecules also have the ability to also carry medicaments such as anti-
24 inflammatories and antimicrobials which will be of considerable benefit in controlling pulpal
25 inflammation and any residual caries, and many of these scaffolds also swell in the presence of
26 moisture which may be beneficial in providing a seal from the oral environment. In considering the
27 possibility of a biomimetic PCA, one must remember that tertiary dentinogenesis occurs in the pulp,
28 and through creating an environment similar to dental pulp it may be possible to speed up the process
29 of reparative dentinogenesis with fewer unwanted side effects. As such, a scaffold loaded with
30 biomimetic bioactive molecules may prove to be an ideal pulp capping material, fulfilling the key
31 requirements of a PCA according to Bjørndal *et al.*, which include; 1) an immediate seal of the dental
32 cavity, protecting the pulp as a dentine bridge is forming, 2) biocompatibility and non-cytotoxic, 3)
33 possess bioactive properties capable of triggering the biological mechanisms for dentine bridge
34 production (Bjørndal et al., 2019).
35
36
37
38

39 From the literature, bioactive molecules may be added to scaffolds as gene therapy (DNA) or proteins
40 for dentinogenic pulp capping. Gene therapy eliminates the need for externally produced recombinant
41 factors, and gene transfection can enhance the efficacy of stem cell applications (Yang et al., 2009).
42 Some bioactive molecules (for example Bone Morphogenetic Proteins (BMPs)) have a short half-life
43 and are required in high concentrations at the local site to be effective; therefore the ability for local
44 elevated production of BMP proteins by the patient may be advantageous and could be achieved via
45 gene transfection (Nakashima, 1994a; Nakashima and Reddi, 2003).
46
47
48
49

50 Purpose and Scope

51 The purpose of this review is to explore the literature surrounding extracellular bioactive molecules
52 known to be sequestered in dentine (as per the works by Austah et al., 2019; Schmalz et al., 2017;
53 Smith et al., 2012; Smith et al., 2016; Tomson et al., 2017; Goldberg et al., 2011), and summarise the
54 current evidence behind their utility as PCAs.
55

56 It is pertinent in biomaterial engineering to consider the delivery mechanism (or carrier) when
57 considering delivery of any molecules, as spatiotemporal control over the release of bioactive
58 molecules controls the resulting tissue regeneration (Rambhia and Ma, 2015). However, extensive
59
60

1
2
3 coverage of carriers for pulp capping is beyond the scope of this review and warrants a review unto
4 its own.
5

6 For all molecules discussed, we have focused on literature published in the English language, with a
7 preference for best and most recent evidence behind the use of each molecule, namely *in vivo* studies
8 over *in vitro* work where available and focused on studies specifically addressing pulp capping.
9 However, there is a general lack of large scale works in this field, with most publications being small-
10 scale singular animal or *in vitro* studies, hence this review attempts to accumulate the most pertinent
11 works for each molecule and evaluate the current evidence behind its utility for inclusion within a pulp
12 capping agent.
13
14
15
16

17 Extracellular Bioactive Molecules Known to be Sequestered in 18 Dentine 19

20 Anabolic/Dentinogenic and Mitogenic 21

22 Transforming growth factors (TGF- β) 23

24 Transforming growth factors (isoforms TGF- β 1, TGF- β 2 and TGF- β 3) are multifunctional cytokines
25 secreted following initial inflammatory response, are potent modulators of tissue repair and are
26 expressed by all cells in the human body (Vander Ark et al., 2018; Niwa et al., 2018). TGF- β s at a cellular
27 level are known to regulate proliferation, migration, differentiation and apoptosis, and more generally
28 they play a role in regulation of inflammatory responses and both tumour suppression and progression
29 (Vander Ark et al., 2018). Factors such as pH, integrins and various proteases (e.g. MMP2, MMP9,
30 plasmin) are known to activate TGF- β s (Niwa et al., 2018). TGF- β 1, TGF- β 2 and TGF- β 3 are receptor
31 ligands which bind to TGF- β receptors (TGF- β receptor 1, TGF- β receptor 2 and TGF- β receptor 3)
32 (Vander Ark et al., 2018), with TGF- β 1 being the predominant isoform (Niwa et al., 2018). Within pulpal
33 inflammation, TGF- β 1 is involved in; chemotaxis of inflammatory cells, angiogenesis, deposition of
34 extra-cellular matrix and the formation of new tissue (About et al., 2000a), and is known to play a role
35 in the differentiation of odontoblasts (Begue-Kirn et al., 1992; Nakashima, 1992). Within the pulp,
36 TGF- β 1 is activated through degradation of the TGF- β 1 complex, leading to elevated dentin
37 sialophosphoprotein (DSPP) and matrix metalloproteinase 20 (MMP20) levels (Niwa et al., 2018).
38
39
40
41

42 TGF- β 1 interacts with the extra-cellular matrix (ECM) in a unique way. TGF- β 1 is secreted as a
43 homodimer, non-covalently attached to its latency associated pro-peptide (LAP). When bound to LAP,
44 TGF- β 1 is prevented from attaching to cell receptors (and is therefore latent (TGF- β 1-LAP)). TGF- β 1-
45 LAP is bound and stored in the ECM via latent TGF- β 1 binding protein (LTBP-1). Mechanical forces
46 within the ECM (from actin and myosin cellular contractions) are transmitted to a binding site in LAP,
47 which induces a hypothetical conformation change, liberating the bound TGF- β 1. In essence, a pulling
48 mechanism from a cellular-bound integrin releases the TGF- β 1 from the ECM-bound TGF- β 1-LAP.
49 Application of the force to the TGF- β 1-LAP without a mechanical anchor (provided by the LTBP-1
50 binding to the ECM), would result in dragging/translocation of the complex and no conformational
51 change facilitating the release of TGF- β 1 (Hinz, 2015). This storage and release mechanism from the
52 ECM produces a disjoint between secretion time and action time of TGF- β 1 (Hinz, 2015).
53
54
55

56 There are numerous *in vitro* studies within the literature proving the ability of TGF- β 1 for inducing
57 odontogenic differentiation of isolated dental pulp stem cells (DPSC)s (Begue-Kirn et al., 1992; Begue-
58 Kirn et al., 1994). However, this review is focused on the potential of bioactive molecules being used
59 as pulp capping agents and currently there is only one human *in vivo* study within the literature.
60

1
2
3 Therefore, most of the current best evidence for the use of TGF- β 1 as a bioactive molecule comes
4 from *in vivo* animal models; the evidence for use of TGF- β s as a bioactive molecule for pulp capping
5 are discussed below.
6

7
8 In the only *in vivo* human study, it has been demonstrated that TGF- β 1 loaded onto collagen
9 membranes (20 ng/ml, 5 μ l) can act as a suitable pulp capping agent, producing similar effects to
10 Ca(OH)₂, but with earlier induction of angiogenesis (Kunarti, 2008). However, this study used sound
11 premolars scheduled for extraction due to orthodontic reasons, with a follow up of only 21 days,
12 making comparison to routine clinical use (i.e. a carious tooth with a long-term restoration) difficult,
13 though the initial results appeared promising.
14

15
16 Using a dog model, Li *et al* (Li *et al.*, 2014) formed a chitosan bilayer membrane, containing TGF- β 1
17 loaded chitosan microspheres and compared the effectiveness of this loaded biomaterial for pulp
18 capping against an unloaded chitosan scaffold, no pulp cap, and Ca(OH)₂. They found that all agents
19 and the control group induced an initial inflammatory response, but only the Ca(OH)₂ and loaded
20 chitosan groups produced reparative dentine – and of these, the loaded chitosan scaffold produced
21 3-6 times more reparative dentine than Ca(OH)₂. In an earlier dog model study by Tziafas *et al.*, (Tziafas
22 *et al.*, 1998), TGF- β 1 loaded filters formed odontoblasts and dentine, and were more successful than
23 basic fibroblastic growth factor (FGF) and Insulin growth factor (IGF) in producing dentine. Similar
24 findings were also identified by Zhang *et al.*, (Zhang *et al.*, 2008) using a goat model with TGF- β 1 loaded
25 onto poly(lactic-co-glycolic acid) microspheres used for pulp capping. They found a higher
26 concentration of TGF- β 1 (400 ng) formed a better tertiary dentine bridge than lower concentrations
27 (20 ng): all of their negative controls produced no dentine.
28

29
30 Conversely, in a rat study by Oliva-Rodríguez *et al* (Oliva-Rodríguez *et al.*, 2011), TGF- β 1 loaded onto
31 alginate microparticles, specifically designed for controlled release, produced a similar result to
32 Ca(OH)₂ for pulp capping. However, with the addition of BMP-7 to the TGF- β 1 loaded alginate, the
33 effects were improved (Oliva-Rodríguez *et al.*, 2011).
34

35
36 When comparing TGF- β 1 to other bioactive molecules, TGF- β 1 has been shown to outperform BMP-7
37 and WNT signalling protein (WNT-1). In a porcine model study, a calcium silicate based material was
38 soaked in a solution containing BMP-7, TGF- β 1 or WNT-1, and each bioactive molecule was assessed
39 for pulp capping. Each calcium silicate scaffold was soaked in 30 μ L of a 300 mg/mL porcine albumin
40 solution containing 30mg of the bioactive molecule. TGF- β 1 instigated odontoblastic differentiation
41 and more consistent reactive dentine formation of an appropriate depth and structure for effective
42 pulp capping (Tziafas *et al.*, 2017). Hu *et al.*, (Hu *et al.*, 1998) have also shown that TGF- β 1 loaded on
43 a collagen scaffold can outperform Platelet Derived Growth Factor (PDGF) BB, Basic Fibroblastic
44 Growth Factor, Epidermal Growth factor (EGF), Insulin-like Growth Factor (IGF) and Ca(OH)₂ in a rat
45 animal model. In contrast to the studies supporting the use of TGF- β 1, Nakashima reported no dentine
46 formation and impaired pulpal healing with TGF- β 1 (2 μ g) loaded on collagen and implanted into a
47 dog model (Nakashima, 1994a).
48

49
50 Based upon these studies, it is possible that the release frequency and carrier may have an effect on
51 the activity of TGF- β 1 in inducing tertiary dentinogenesis and reparative pulpal changes. However, It
52 is also clear that TGF- β 1 may be as good, if not better than Ca(OH)₂ as a PCA. Modification of the
53 delivery mechanism to incorporate synergistic growth factors could be promising for improved results.
54 The wealth of literature supporting TGF- β 1 makes it a front-runner for inclusion in a biomimetic PCA,
55 despite it being more than 10 years since the *in vivo* human study. It is not clear why exploration of
56 this bioactive molecule for use as a PCA has slowed when it shows such promise. Further clinical trials
57 are needed to forward research on this growth factor.
58
59
60




Figure 1: Schematic diagram summarising the bioactive molecules sequestered in dentine that have been explored in the literature, and this review, for pulp capping dentinogenesis. Molecules with the most evidence supporting their use are in green, amber for intermediate evidence and little evidence in grey. Molecules in grey have been included for completeness. Interactions are shown by arrows. DMP1= Dentine Matrix Protein 1, OPN= Osteopontin, BSP= Bone Sialoprotein, DSPP = Dentine Sialophosphoprotein DSP= Dentine Sialoprotein, DPP= Dentine Phosphoprotein, MEPE= Matrix Extracellular Phosphoglycoprotein, SIBLINGS= Small Integrin-Binding Ligand, N-linked Glycoproteins NGF= Nerve Growth Factor, SCF= Stem Cell Factor, TGF= Transforming Growth Factors BMP= Bone Morphogenetic Proteins, EGF = Epidermal Growth Factor, IGF= Insulin-Like Growth Factor, FGF= Fibroblastic Growth Factor, VEGF= Vascular Endothelial Growth Factor, HGF= Hepatocyte Growth Factor, PDGF= Platelet Derived Growth Factor, PIGF= Placental Growth Factor, GMCSF= Granulocyte Macrophage Colony Stimulating GCSF= Granulocyte Colony Stimulating Factor, IgA = Immunoglobulin A, IgG = Immunoglobulin G, IgM = Immunoglobulin M, SLRPS = Small leucine-rich proteoglycans, GDNF = Glial Derived Neurotrophic Factor, BDNF = Brain Derived Neurotrophic Factor, MMP = Matrix Metalloproteinase

Bone Morphogenetic Proteins (BMPs)

Morphogens are extracellularly secreted signals governing morphogenesis and control craniofacial patterning. Morphogens are subdivided into four evolutionarily conserved protein families; BMPs, Fibroblast Growth Factors, hedgehog proteins and wingless-and int-related proteins (Nakashima and Reddi, 2003). BMPs are a family of 22 secreted extracellular matrix-associated proteins involved in numerous functions within the human body, such as muscle development, stem cell and organ formation, bone and cartilage formation, iron metabolism and vascular biology (Brazil et al., 2015; Nakashima and Reddi, 2003). BMPs are considered part of the TGF- β family, with both acting on Smad intracellular signalling (TGF- β utilising Smad1/5/8, BMPs utilising Smad2/3) (Brazil et al., 2015; Nakashima and Reddi, 2003).

In the literature, BMPs have been added to scaffolds as gene therapy (DNA) or proteins for dentinogenic pulp capping. BMPs have a short half-life and are required in high concentrations at the local site to be effective; therefore the ability for local elevated production of BMP proteins by the patient may be advantageous and could be achieved via gene transfection (Nakashima, 1994a; Nakashima and Reddi, 2003).

Again, similar to TGF- β 1, there is a wealth of literature confirming the role of BMPs in dentinogenesis, and their ability to induce odontogenic differentiation (About et al., 2000b; Chen et al., 2008; Iohara et al., 2004; Suzuki et al., 2011). However, there is considerably less literature covering the use of BMPs specifically as pulp capping agents for *in vivo* applications and for this, one must look to animal models again, as there are no clinical trials within the literature covering their use. The main BMPs explored within the literature are BMP2 and BMP7.

Some of the earliest work on BMPs for pulp capping was carried out by Nakashima (Nakashima, 1994b; Nakashima, 1994a), who explored BMPs for pulp capping in a dog model. Briefly, across two studies they explored the use of recombinant BMP-2 and BMP-4 carried on a collagen matrix (Nakashima, 1994a) and mixed with inactivated, demineralized dentine matrix powder (particle size 200-500 μ m size) (Nakashima, 1994b). When used in conjunction with collagen, BMP-2 (2 μ g) and BMP-4 (4 μ g) induced osteodentine formation, however tubular dentine was lacking, and interestingly, the unloaded collagen carrier control produced a very minimal amount of osteodentine (Nakashima, 1994a). When used in conjunction with inactive, demineralised powdered dentine, 2 μ g of BMP-2 and BMP-4 demonstrated osteodentine towards the superficial aspect of the cavities and tubular dentine towards the deeper radicular aspects (Nakashima, 1994b).

BMP-2 has been explored as a pulp capping agent in conjunction with MTA; 1 g MTA mixed with 1 μ g BMP-2 was compared to MTA alone and no difference in the quality and quantity of reparative dentine was seen between the rat groups, and in both scenarios the reparative dentine had a bone-like morphology (Ko et al., 2010).

An example of BMP gene therapy being used can be found in the study by Yang et al (Yang et al., 2009), who used an adenoviral vector containing human *BMP-2* transfected into DPSCs and loaded onto a sintered ceramic scaffold; *in vitro* and *in vivo* experiments demonstrated mineralised tissue formation, but the appearance again was more in-keeping with bone than dentine. In an attempt to explain the formation of bone over dentine, the authors suggested that BMP-7 may be a more appropriate candidate for dentine production, and that the scaffold structure and environment (at a micro and macro level) may play a role in the formation of bone over dentine from cells of dental pulp origin. Subsequently, BMP-7 carried on nanofibrous poly(L-lactic acid) scaffolds has been used successfully *in vitro* and *in vivo*, to push odontoblastic differentiation and dentine-like hard tissue formation (Wang et al., 2010).

1
2
3 When BMP-7 was compared to MTA as a pulp capping agent in rats, MTA out-performed BMP-7, with
4 a more impervious dentine bridge being formed in the MTA group and increased DSP activity. The
5 group found that the material produced by BMP-7 also resembled bone more than dentine (Andelin
6 et al., 2003). However, in this study BMP-7 was added to the pulp exposures without the adjunct of a
7 scaffold, highlighting the potential importance of the scaffold in BMP delivery, likely for timely and
8 sustained release, and potentially structural direction in influencing tubular dentine deposition over
9 osteodentine.
10

11
12 For pulp capping, BMP-7 and Bone Sialoprotein (BSP) (each delivered on a gelatin carrier) have been
13 shown to produce more mineralised tissue than $\text{Ca}(\text{OH})_2$ in a rat model (Goldberg et al., 2001). The
14 BMP-7 group produced more tissue towards the apical and radicular areas of the pulp, whereas the
15 BSP group produced dentine more in the coronal area, and the dentine produced by the BSP group
16 was more like tubular dentine than the BMP-7 group and less pervious (Goldberg et al., 2001). The
17 preferential production of osteodentine in the radicular area of the pulp was also found by Six *et al*
18 (Six et al., 2002b) exploring BMP-7 on collagen scaffolds as pulp caps.
19

20
21 Rutherford *et al.*, explored the use of BMP-7 using primate animal models (Rutherford et al., 1993;
22 Rutherford et al., 1994). Using a powdered collagen matrix mixed with recombinant human BMP-7
23 (2.5 $\mu\text{g}/\text{mg}$ of collagen), they compared BMP-7 to $\text{Ca}(\text{OH})_2$ (Rutherford et al., 1993) and explored the
24 tertiary dentine formation at different time points post-operatively (Rutherford et al., 1994). In
25 summary, BMP-7 outperformed $\text{Ca}(\text{OH})_2$ in the short term (Rutherford et al., 1993) and demonstrated
26 75% tertiary dentine bridge formation at 1 month and 95% at 4 months (Rutherford et al., 1994).
27 Similar to other studies, the unloaded collagen carrier failed to produce a dentine bridge. From the
28 descriptions in these studies, the dentine produced seems to be a mix of tubular and osteodentine.
29

30
31 More recent studies have attempted to discover the optimum dosage of unloaded BMP-7 to push
32 odontogenic differentiation in culture of DPSCs and maintain DPSC proliferation: 50 ng/mL and 100
33 ng/mL were the most successful (Zhu et al., 2018).
34

35
36 One issue with many of these studies is that sterile, uninfamed teeth were used. This is an issue
37 Rutherford and Gu attempted to resolve by exploring BMP-7 delivered on collagen scaffolds to
38 inflamed ferret pulps. The results showed no reparative dentinogenesis, possibly in relation to
39 elevated BMP antagonistic binding proteins present in inflamed dental pulps inactivating the protein
40 (Rutherford and Gu, 2000). Rutherford (Rutherford, 2001) went on to explore whether *in vivo* gene
41 transfection of *BMP-7* in an adenovirus within a collagen hydrogel carrier could induce reparative
42 dentine formation in inflamed ferret pulps and compared this to autologous fibroblasts transfected
43 with *BMP-7 ex vivo*, also carried in a collagen hydrogel into the inflamed pulps. The direct transfection
44 group did not produce reparative dentine, however the group with pulps capped using the *ex vivo*
45 transfected fibroblasts did produce good quality reparative dentine with associated odontoblasts. The
46 authors postulated that this may be due to sustained secretion by the fibroblasts of BMP-7.
47

48
49 Recombinant BMP-2 is marketed commercially for bone regeneration (InductOs [™], Medtronic
50 BioPharma, The Netherlands) as well as recombinant BMP-7 (Osigraft [™], Olympus Biotech, Ireland),
51 however both of these systems have variable success rates and little long-term clinical evidence
52 supporting their use (Ayoub and Gillgrass, 2019; Calori et al., 2015; Chevet-Noël et al., 2020;
53 Corinaldesi et al., 2013; Sailhan et al., 2010; Vincentelli et al., 2019) . No research has been undertaken
54 using these materials off-label for dental pulp capping, though the systems used are similar to the
55 experimental work carried out using recombinant BMP-2 and BMP-7 and this could be a specific area
56 of interest moving forwards.
57
58
59
60

1
2
3 Blended scaffolds have also been used to successfully deliver plasmid vectors coding for *BMP-7*. In the
4 study by Yang *et al.*, (Yang *et al.*, 2012) chitosan/collagen scaffolds (one containing a plasmid coding
5 for human *BMP-7* and one control) were seeded with DPSCs and implanted subcutaneously in mice.
6 They were reviewed after 4 weeks and upregulation of DSPP was observed (suggesting odontoblastic
7 differentiation) in both groups, but this was significantly higher in the *BMP-7* group.
8
9

10 In summary, *BMP-2* and *BMP-7* have been used to varying degrees of success as pulp capping agents
11 in animal studies. It is clear from the literature though that a bone phenotype may result in the hard
12 tissue produced, and this seems to occur more readily when the *BMP* is not delivered on a scaffold.
13 This is not ideal for pulp capping as bone is more porous than dentine and can therefore be pervious,
14 preventing a suitable pulp seal. It is not currently known what causes a bone phenotype over a dentine
15 phenotype; the carrier, the environment, the use of proteins or DNA may all play a role, and further
16 work is needed to resolve this issue should *BMPs* be pursued as a potential pulp capping bioactive
17 molecule. The limitations of requiring a high concentration of *BMPs* required to produce dentine, the
18 possibility of inflammation impeding their action and the short half-life of these molecules are
19 significant hurdles. Although there is considerable literature exploring *BMPs* as PCAs and clinical
20 application of these molecules has reached the commercial market for bone regeneration, dentine is
21 not the same as bone, and until the issue of bone production over dentine production is resolved and
22 controlled *BMPs* may prove less suitable for PCAs than *TGF- β 1*, and other molecules (discussed below)
23 may show more promise.
24
25

26 27 Insulin-like growth factor

28 The IGF (insulin-like growth factor) system is complex, being comprised of two ligands (*IGF-I* and *IGF-II*),
29 two cell surface receptors, at least six IGF binding proteins (*IGFBP*) and multiple proteases (Catón
30 *et al.*, 2007). *IGF-1* is covered most widely in the literature; a cell surface receptor tyrosine kinase that
31 binds to *IGF-I* and *IGF-II* receptors, to activate various downstream signalling pathways, such as
32 *AKT/Protein Kinase B* (a signal transduction pathway) and *Mitogen-Activated Protein Kinase (MAPK)*
33 (*Teng et al.*, 2018). *IGF-1* has been implicated in the differentiation and proliferation of dental pulp
34 stem cells (*DPSC*) along odontogenic and osteogenic lineages (via the *MAPK* pathway) (*Lv et al.*, 2016;
35 *Nakashima*, 1992). *IGF-1* has also been shown to play a role in tertiary dentine formation; a mouse
36 study by *Matsumura et al* (*Matsumura et al.*, 2017) showed that tertiary dentine volume was reduced
37 following odontoblast-specific *IGF-I* ablation. *IGF-I* signalling is also implicated in cell stemness,
38 including cancer cell stemness, and resistance to chemotherapy, which has raised concerns over its
39 use (*Teng et al.*, 2018).
40
41
42

43 Limited *in vivo* work has been completed to explore the use of *IGF-1* as a bioactive molecule in pulp
44 capping. In a rat study by *Lovschall, Fejerskov and Flyvbjerg* (*Lovschall et al.*, 2001), the efficacy of
45 *IGF-1* as a potential pulp capping bioactive molecule was proven; recombinant *IGF-1* (400 ng) was
46 loaded onto methylcellulose gels and compared against methylcellulose gels loaded with saline, and
47 *Ca(OH)₂*. In all of the teeth examined histologically, dentine bridges covered more than 50% of the
48 pulp, however significantly more tertiary dentine was identified in the *IGF-1* loaded group.
49
50

51 When looking at *IGF-2* for pulp capping in a rat model, *Hu et al* (*Hu et al.*, 1998) found fibrous tissue
52 repair only for *IGF-2*, and found that by comparison *TGF-B1* proved to be more effective for pulp
53 capping.
54

55 With little experimental animal data, *IGF-1* and *IGF-2* need considerably more evidence regarding its
56 efficacy before it is widely considered as a potential bioactive molecule for pulp capping. As very little
57 recent work has been done on *IGF-1* for pulp capping, it would seem that this bioactive molecule has
58 largely been side-lined in favour of other molecules, such as *TGF- β 1*. Concerns over carcinogenesis
59 may be limiting the exploration of this growth factor for use as a pulp cap.
60

Fibroblastic Growth Factor 2

There is sparse literature surrounding the use of Fibroblastic Growth Factor 2 (FGF-2) for pulp capping to produce a dentine bridge, despite it being implicated as a potential bioactive molecule in DPSC differentiation (Nakashima, 1992). FGF-2 is known to be a promoter of stem cell homing, stemness, proliferation and angiogenesis (Lim et al., 2017; Smith et al., 2016).

Very few *in vivo* studies demonstrating pulp capping with FGF-2 exist, despite the fact that it has been long established that FGF-2 can elicit tertiary dentinogenesis (Hu et al., 1998) (though admittedly to a lesser extent than TGF- β 1 in this study). One *in vivo* study exploring this further is by Kikuchi *et al.*, (Kikuchi et al., 2007) where collagen sponges mixed with FGF-2 loaded gelatin hydrogels were implanted into the exposed upper molars of rats. This provided a controlled release of FGF-2, and was compared against pulps capped with free FGF-2 and the collagen sponge/gelatin hydrogel mixture alone. The free FGF-2 group demonstrated tertiary dentine formation in the residual pulp only, whereas with controlled release of FGF-2, the tertiary dentine formation was over the pulpal exposure. This demonstrates that the control release of FGF-2 is pertinent to the formation of dentine in a pulp cap. In later work by the same group, different concentrations of FGF-2 were explored as PCAs loaded in their collagen sponge/gelatin hydrogel carrier and implanted into exposed rat pulps: DPSCs and vessels invaded the scaffold and dentine was produced. A concentration of 0.5mg/ml of FGF-2 was found to produce the highest volume of tertiary dentine (Ishimatsu et al., 2009).

FGF-2 has been (like many of the bioactive molecules sequestered in dentine) more widely explored for bone regenerative purposes and proved to be successful in animal models (e.g. Behr et al., 2012; Hong et al., 2010; Kigami et al., 2013), and it is likely only a matter of time before exploration of FGF-2 picks up speed in the field of pulp capping and the limited current evidence is very encouraging. It does seem that controlled release of this molecule is key to its efficacy in sealing the pulp, so careful consideration of the scaffold onto which it is loaded is required and further work on identifying the ideal scaffold for this molecule's release into the pulp.

Epidermal Growth Factor

Epidermal Growth Factor (EGF) was first isolated from mouse salivary glands and is part of an EGF family of ligands, and when bound to their high-affinity receptors, these ligands have powerful mitogenic activities. After binding, EGF is known to activate two major intracellular pathways to invoke cell proliferation and cytoprotection (Berlanga-Acosta et al., 2009), and EGF is implicated in DPSC migration (Howard et al., 2010). Although important for repair and regeneration of tissues, the actions of EGF are also implicated in tumour progression (Xu et al., 2017).

Very little work has been completed on exploring EGF in dental pulp capping – possibly (similar to IGF-1) due to its known links to tumour progression. Most of the research on EGF for pulp capping is over twenty years old. As an example, Hu *et al.*, explored Platelet Derived Growth Factor (PDGF) and EGF (5 ng/ μ l and 2 ng/ μ l respectively) soaked onto a collagen membrane and inserted into exposed rat incisor. They found a combination of PDGF-BB and EGF to out-perform Ca(OH)₂ and the unloaded collagen membrane (Hu et al., 1997). Hu *et al.*, went on to explore EGF, again on collagen membranes in a rat model, in comparison to other bioactive molecules (TGF- β 1, PDGF-BB, IGF II, basic fibroblastic growth factor (bFGF)) and compared it to the unloaded collagen carrier and Ca(OH)₂. TGF- β 1 proved to be the best at producing a dentine bridge with a tubular quality and limited pulpal inflammation. However, the authors noted that the other molecules may have therapeutic utility when used in unison, though this required further exploration (Hu et al., 1998).

The fact that other bioactive molecules have been shown to out-perform EGF limits the exploration of this molecule as a sole agent in pulp capping. However, its utility as a powerful mitogen, ability to increase cell proliferation and role in cytoprotection may prove incredibly valuable in the typically inflamed environment where pulp caps are used. For these reasons it may be beneficial to consider EGF as beneficial adjunct in PCAs, to be used with more established molecules such as TGF- β 1.

Angiogenic

Vascular Endothelial Growth Factor

Vascular Endothelial Growth Factor (VEGF), has been explored considerably in pulp regeneration (Al-Hassiny et al., 2019), likely due to its angiogenic properties in potential revascularisation of the pulp, though little work has been done covering this bioactive molecule for pulp capping.

VEGF is well known for its angiogenic properties, and this has been demonstrated to also be the case for dental pulp tissue (Al-Hassiny et al., 2019; Zhang et al., 2011), but for successful dental pulp capping, a hard dentine bridge is required. VEGF, when bound to its receptor has several functions; it stimulates endothelial cell proliferation, increases blood flow, facilitates chemotaxis and increases capillary hyperpermeability (Al-Hassiny et al., 2019; Matsushita et al., 2000).

VEGF has a comparatively short half-life (Zhang et al., 2014) and is expressed throughout the DPC in both mature and immature teeth, and has been shown to have an effect on mineralisation and odontoblastic differentiation in the early stages of DPSC differentiation (Aksel and Huang, 2017). It is capable of causing odontoblastic differentiation of DPSCs via gene transfection *in vitro* (Zhang et al., 2014) demonstrating its potential use as a PCA. The short half-life means, that without gene transfection, VEGF recombinant protein will require a carrier for sustained release. A chitosan/ β -glycerophosphate scaffold carrying 100 ng/ml of VEGF protein has been used successfully *in vitro* to achieve odontoblastic differentiation of DPSCs, and the use of a carrier facilitated controlled release with better mineralisation than VEGF alone (Wu et al., 2019).

Much of the work on VEGF for pulp capping has only been accomplished in the last five years, possibly due to dental researchers focusing solely on its angiogenic role (as implied by its name) and failing to consider the other roles this bioactive molecule may have and subsequent therapeutic gains to be developed by exploring it further. To date, no *in vivo* studies on animals or humans have been carried out to explore VEGF as a PCA. The short half-life means that controlled and sustained release may be necessary to have any significant effect. Its role in odontoblastic differentiation warrants further exploration.

Hepatocyte Growth Factor

It has long been established that pulpitis increases Hepatocyte Growth Factor (HGF) expression in the dental pulp (Ohnishi et al., 2000; Ohnishi and Daikuhara, 2003), and that HGF is a potent mitogen and morphogen, and has angiogenic and cellular motility effects (Ye et al., 2006).

In vitro work has also demonstrated that HGF can increase DPSC proliferation and odontoblastic differentiation (Ye et al., 2006). As HGF is also released from dentine matrix, it is thought to contribute to cellular signalling events in the repair of the DPC (Tomson et al., 2013). FGF-2 is thought to stimulate the secretion of both HGF and VEGF, leading to an increase in angiogenesis (Gorin et al., 2016) in the dental pulp. As HGF has demonstrated multiple roles *in vitro* in the healing of the DPC, it could be a powerful additive to a biomimetic PCA. To date HGF has not been explored as a PCA *in vivo* – it will be interesting to see how our knowledge of this peptide and its role in tertiary dentinogenesis increases with time, though the initial work completed on this molecule is promising.

Platelet Derived Growth Factor

PDGF is known to stimulate pulp cells and push their differentiation into odontoblasts (Nakashima, 1992; Zhang et al., 2017b). PDGF is present in dentine matrix (Roberts-Clark and Smith, 2000), and consists of a family of 5 polypeptides (PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD), with PDGF-BB the most widely explored as it interacts with all three PDGF receptors (Zhang et al., 2017b). PDGF is known more generally to be a powerful mitogen, with potent angiogenic effects, and is a key mediator in wound healing and tissue regeneration (Zhang et al., 2017b). It is also known to be a powerful chemoattractive agent for mesenchymal stem cells and DPSCs (Zhang et al., 2017b). Positive synergistic effects have been noted *in vitro* for PDGF with TGF- β 1 and dentine non-collagenous proteins, leading to increased cell viability and proliferation when compared to each of these factors alone (Tabatabaei and Torshabi, 2016).

PDGF-BB has been shown to be capable of stimulating tertiary dentinogenesis (Hu et al., 1998), though in the study by Hu *et al.*, its effects were not as great as TGF- β 1, possibly limiting the exploration of this molecule more widely in the literature. Similar to HGF, the multiple roles this molecule likely plays in the healing of the DPC necessitates a better understanding of its potential therapeutic role in dentistry. More *in vivo* work is needed to establish the role of PDGF in dentinogenesis for pulp capping, though presently it would seem that this peptide would most likely play a synergistic role in a biomimetic PCA, likely coupled with another molecule.

Placental Growth Factor

Placental Growth Factor (PIGF), present in dental matrix (Roberts-Clark and Smith, 2000), is thought to play a role in osteoblastic differentiation (McCoy et al., 2013) and angiogenesis (Kinnaird et al., 2004). As of yet, PIGF has not been explored fully to elucidate its role in tertiary dentinogenesis, and no *in vivo* work has been accomplished. Because of this, it is currently very difficult to see what role PIGF may have in a biomimetic PCA, and is included in the review only as a matter of completeness.

Inflammatory Cytokine

Interleukins

Inflammatory cytokines have been shown to be present in dentine components sequestered in pulp capping and caries. Evidence also indicates towards a reparative role of low grade inflammatory processes (such as those induced by dental injury), contributing to DPC repair (Tomson et al., 2017). Interleukins IL-1 α , IL-1 β , IL-4, IL-6, IL-8 and IL-12 are sequestered in dentine, with IL-8 having the most abundant expression (Cooper et al., 2010).

Interleukins are secreted proteins, capable of binding to specific receptors, and are known to play a role in the communication among leukocytes (Akdis et al., 2011). Although interleukins are traditionally considered inflammatory molecules, they are known to be present in dentine, and their associated inflammatory response is widely considered an integral part of the regenerative process of dental pulp capping (Cooper et al., 2010; Smith et al., 2012). However, careful modulation and resolution of the inflammatory process is key to facilitating regeneration and covered in a comprehensive review by Smith *et al.*, (Smith et al., 2012). The balance between mild inflammation facilitating the eradication of carious bacteria and their toxins, and regeneration is delicate and complex. If the inflammatory response is too great, the tooth will lose vascularity and become necrotic; if it is too little, deleterious stimuli will remain, leading to increased tissue damage. It is perhaps because of this refined interplay between inflammation and regeneration that interleukins have not been widely explored in the literature as a potential bioactive molecule to add to a PCA. As exogenous interleukins may add to and affect the balance of inflammation/regeneration, it would be

1
2
3 better to avoid their usage as additives to PCAs until we can better understand therapeutic levels of
4 these proteins.
5
6

7 Colony Stimulating Factors (GMCSF and GCSF)

9 Granulocyte Macrophage Colony Stimulating Factor (GMCSF) and Granulocyte Colony Stimulating
10 Factor (GCSF) are members of the 'Colony Stimulating Factor' group of glycoproteins, and are known
11 to be present in the inflamed pulp (Tomson et al., 2017). The Colony Stimulating Factor group of
12 glycoproteins stimulate the senescence, proliferation, and differentiation of haematopoietic cells
13 (Nakashima and Iohara, 2017; Trapnell and Abe, 2006).
14

15
16 The secretion of GMCSF (and osteopontin) by immunocompetent cells at the dentine-pulp junction,
17 locally induces maturation of dendritic cells, thus encouraging increased activity of odontoblasts and
18 their differentiation from pulpal resident progenitors, causing speculation over the potential role of
19 GMCSF in odontoblastic differentiation (Saito et al., 2011). GCSF has been shown to be effective at
20 mobilising DPSCs (Nakashima and Iohara, 2017), which is essential for the replacement of apoptosed
21 odontoblasts at the dentine-pulp junction, necessary for tertiary dentinogenesis.
22

23
24 GCSF with autologous isolated DPSCs, on a collagen scaffold, has been shown to be capable of
25 regenerating a DPC in a dog model. For this study, numerous control groups were used, though
26 unfortunately none with GCSF alone, making it difficult to attribute the regeneration to solely GCSF
27 (Iohara et al., 2013). GCSF has also been shown to be beneficial in inducing mineralisation for
28 dentinogenesis *in vitro* (Takeuchi et al., 2015).
29

30
31 Little work has been done to explore the roles that GMCSF and GCSF may play in *in vivo* pulp capping,
32 and the potential that harnessing these bioactive molecules may have in aiding DPSC recruitment
33 (possibly even to a suitable acellular scaffold that is capable of being colonised), and differentiation
34 for reparative dentinogenesis. Although both molecules are currently used therapeutically in
35 haematological malignancies, more *in vitro* and animal work is required before they can be considered
36 suitable for human clinical trials in pulp capping and until we have a better understanding of the
37 potential role of these molecules in biomineralisation, it is unlikely that they would be used as sole
38 agents in any PCA that is designed in the near future
39

40 Immunoglobulins

41
42 Immunoglobulins, also known as antibodies, are Y-shaped glycoproteins predominantly produced by
43 plasma cells. Immunoglobulins IgA, IgG and IgM and believed to be sequestered in dentine (Schmalz
44 et al., 2017). It is likely that they would play a role in the defence against cariogenic bacteria (Smith
45 et al., 2012). The role of immunoglobulins in production of a hard tissue dentine bridge is entirely
46 speculative, with no evidence of their inclusion in experimental PCAs in the literature (Smith et al.,
47 2012), making the case for inclusion of them in an experimental PCA difficult. Nevertheless, their role
48 in combatting any residual caries would prove beneficial in a PCA, if an alternative more broad-
49 spectrum anti-microbial was not included, and they are included in this review only for completeness.
50

51 Chemotactic

52 Stem Cell Factor

53
54 Stem Cell factor (SCF) is a chemokine and homing agent for progenitor cell recruitment and can cause
55 a significant increase in DPSC proliferation (Pan et al., 2013), and has a potential role in the
56 differentiation of DPSCs to become odontoblasts (Ruangsawasdi et al., 2017). SCF is known to be
57 liberated from dentine during pulp capping (Tomson et al., 2017). No *in vivo* pulp capping experiments
58 have been identified in the literature and most of our current knowledge on SCF has emerged in the
59
60

1
2
3 last five years. Exploration and potential exploitation of this bioactive molecule for DPC regeneration
4 is still very much in its infancy and without any evidence supporting its direct role in hard tissue barrier
5 formation, it is likely that SCF would only have a supportive role in DPC regeneration from a PCA. Due
6 to the lack of information surrounding this molecule for dental pulp capping, it is included only as a
7 matter of completeness.
8
9

10 Neurotrophic Proteins

11
12 Neuropeptides have been identified in dental extra-cellular matrix, and are thought to play various
13 roles in pain transduction (Smith et al., 2012). It is widely accepted that neuropeptides are associated
14 with pulp regeneration, neural differentiation and angiogenic events (Li and Wang, 2016; Smith et al.,
15 2016; Zhang et al., 2017a), but specifically tertiary dentinogenesis and pulp capping are less widely
16 explored. Nerve Growth Factor (NGF), Glial Derived Neurotrophic Factor (GDNF), neurotrophin 3,
17 neurotrophin 4/5, and brain-derived neurotrophic factor (BDNF) are all known to be sequestered in
18 dentine with GDNF and neurotrophin 4/5 expressed at the highest levels (Austah et al., 2019; Tomson
19 et al., 2017). The role these molecules may play in pulp capping is poorly understood and an area of
20 recent exploration (Austah et al., 2019). No *in vivo* work has been completed exploring the role of
21 neurotrophic proteins as part of a pulp capping system, though GDNF, BDNF and neurotrophin 4/5 are
22 thought to affect DPSC migration (Xiao et al., 2018; Xiao et al., 2020). Nerve growth factor (NGF) has
23 been shown to play a potential role in differentiation of odontoblasts (Arany et al., 2009; da Rosa et
24 al., 2018a), thereby facilitating dentinogenesis, though no *in vivo* work has been done to confirm this.
25
26

27
28 Currently, the evidence supporting the use of neurotrophic proteins in an experimental PCA is too
29 weak for them to be considered a viable option. It is likely these molecules play a role in the
30 inflammatory pulpal response based upon the literature but there is no evidence that they directly
31 assist with hard tissue barrier formation in the pulp. With further work exploring their actions *in vitro*,
32 and eventually *in vivo*, they may prove useful as an additive to assist in odontoblastic differentiation,
33 but it is difficult to see how they could play a role as a sole agent in a PCA.
34
35

36 Small Integrin-Binding Ligand, N-linked Glycoproteins

37
38 Small Integrin-Binding Ligand, N-linked Glycoproteins (SIBLINGs) are, after collagen, the most
39 abundant peptides in dentine. They are capable of binding to integrin receptors, facilitating cell
40 attachment and signalling. The SIBLING family includes osteopontin (OPN), bone sialoprotein (BSP),
41 dentin matrix protein 1 (DMP1), dentin sialophosphoprotein (DSPP), and matrix extracellular
42 phosphoglycoprotein (MEPE) (Bleicher et al., 2015). Members of the SIBLING family are often used as
43 markers for odontoblast differentiation, though it is important to note that their expression can
44 overlap with osteoblasts and be associated with bone (Smith et al., 2012).
45

46
47 DMP-1 is known to be capable of inducing odontoblastic differentiation of DPSCs and stimulating
48 mineralised tissue deposition (Hao et al., 2002; He et al., 2003; Narayanan et al., 2001). DMP-1 is also
49 thought to play a role in activating pulpal fibroblasts as part of the inflammatory-regenerative process
50 following pulpal damage (Abd-Elmeguid et al., 2012). Work has been achieved in exploring its use for
51 endodontic perforation repair (Alsanea et al., 2011), which found a collagen scaffold loaded with
52 DPSCs and DMP-1 to be capable of repairing a perforation with newly deposited dentine. DMP-1 has
53 been hypothesised to be cleaved by matrix metalloproteinase 2 (MMP-2) into two forms, with the C-
54 polypeptide form having an effect on the differentiation of DPSCs to odontoblasts. The same
55 researchers went on to explore the use of this cleaved form of DMP-1 for pulp capping when loaded
56 onto agarose beads in a rat model and found that the cleaved DMP-1 produced a dentine bridge more
57 quickly than unloaded agarose beads and of a higher quality (Chaussain et al., 2009).
58
59
60

1
2
3 DSPP is immediately cleaved after production, giving rise to Dentine Sialoprotein (DSP) and dentine
4 phosphoprotein (DPP) (Bleicher et al., 2015; Smith et al., 2012). DSP is thought to play a role in DPSC
5 differentiation and hard tissue formation (Li et al., 2017). It is also thought to be involved with
6 migration and activation of immune cells (da Rosa et al., 2018a). DPP is also involved in mineralisation
7 and plays a role in the initial formation of hydroxyapatite crystals (da Rosa et al., 2018a). Very few *in*
8 *vivo* studies focused on exploring the effects of DSPP, DSP or DPP as PCAs are present in the literature.
9 One of these few studies explored a DSP synthetic peptide as a PCA in a dog model (Kim et al., 2009),
10 and compared this to MTA and Ca(OH)₂. The study found more inflammation and less hard tissue
11 deposition in the synthetic DSP group compared to both the MTA and Ca(OH)₂ group, which both had
12 similar results. In a study exploring DPP cross-linked into the fibrils of a collagen scaffold (0.5 µg of
13 DPP to 29.5µg type I atelocollagen fibrils), better quality reparative dentine was found in the
14 experimental group than the control groups of collagen alone and Ca(OH)₂ in a rat model (for example,
15 a lack of tunnel defects and more complete coverage of the pulp) (Koike et al., 2014). Koike *et al.*, also
16 found the rate of dentine deposition to be quicker in the experimental group than the control groups
17 (Koike et al., 2014). Because the DSP synthetic peptide performed so badly compared to other PCAs,
18 it is likely not a key molecule to pursue in the design of a biomimetic PCA. However, the DPP results
19 are encouraging and it may be that out of the two molecules cleaved from DSPP, DPP is the more
20 pertinent for tertiary dentine formation; further work needs to be accomplished exploring DSPP and
21 its products to better understand the roles they play in dentine bridge formation and DPC repair.
22
23
24

25
26 BSP is expressed in tertiary dentine and, similar to DPP, is involved in the initial formation of
27 hydroxyapatite, though following initial production it can also act as an inhibitor (da Rosa et al., 2018a;
28 Smith et al., 2012), therefore it may be better considered a regulator of hydroxyapatite formation. In
29 a study by Six *et al.*, (Six et al., 2002a) the effects of BSP and BMP-7 (both within a gelatin carrier) for
30 pulp capping were compared – as previously discussed. BMP-7 predominantly elicited osteodentine
31 deposition in the coronal and radicular areas of the pulp leading to near total pulpal obliteration,
32 whereas BSP produced more atubular dentine, filling only a third of the crown. Like many of the
33 SIBLINGS, the role of BSP in dentinogenesis has been explored to some degree, but very few studies
34 have been completed assessing its potential role as a PCA. The work by Six *et al.*, (Six et al., 2002a)
35 raises the possibility that BSP may be a better bioactive molecule for inclusion in a PCA than BMP-7,
36 partially due to its more controlled mineralisation effects and also due to a better, more impervious,
37 hard tissue barrier. BSP may indeed be a key component for any future PCAs, and as has been shown,
38 can outperform the more commonly considered BMP group of molecules and warrants further
39 investigation.
40
41

42
43 OPN is another molecule poorly researched for pulp capping, though this may be in part due to its
44 perceived action of inhibiting hydroxyapatite crystal growth (da Rosa et al., 2018a). However, OPN has
45 also been shown to play an essential role in the collagen formation of tertiary dentinogenesis from
46 new odontoblast-like cells (Saito et al., 2016). Although inhibition of hydroxyapatite propagation may
47 seem like the opposite effect to what is required for a PCA, careful and controlled moderation of
48 dentine is essential for a successful clinical outcome – some PCAs (such as MTA (Agamy et al., 2004))
49 can cause pulpal obliteration from excessive dentine deposition, demonstrating a lack of
50 hydroxyapatite inhibition. Further *in vitro* work is required to better understand the role OPN may
51 play in tertiary dentinogenesis prior to consideration of this bioactive molecule in a PCA, though it
52 could be argued that the inhibitory role this molecule plays could be pivotal in controlling the dentine
53 deposited.
54

55
56 The hypothesised functions of MEPE within tertiary dentinogenesis are primarily those of
57 mineralisation regulation and inhibition, and phosphate metabolism (Bleicher et al., 2015; da Rosa et
58 al., 2018a). In further work by Six *et al.*, (Six et al., 2007), they rebuke the idea that MEPE inhibits
59 mineralisation by exploring the actions of Dentonin, a synthetic derivative of MEPE, as a PCA when
60

1
2
3 loaded onto agarose beads. Dentonin was found to have a rapid action on the initial stages of pulpal
4 repair (cell recruitment and cell proliferation). No evidence for mineralisation inhibition was detected
5 in their rat model. As the exact role of MEPE in tertiary dentinogenesis is poorly understood, further
6 work is needed to better understand the potential of this bioactive molecule as a PCA, though it is
7 possible that it plays a regulatory role similar to the other SIBLING molecules.
8
9

10 Small leucine-rich proteoglycans (SLRPS)

11 SLRPs are a family of numerous proteoglycans, which can be subdivided into five classes. They may be
12 extracellular, pericellular (basement membrane zone), cell surface or intracellular, they may also be
13 divided into canonical and non-canonical (Listik et al., 2019). Five SLRPs have been identified in dentine
14 matrix and predentine; Decorin, Biglycan, Fibromodulin, Lumican and Osteoadherin (Orsini et al.,
15 2009).
16
17

18 Decorin and Biglycan have several hypothesised roles in dentinogenesis; i) collagen stabilisation, ii)
19 collagen fibrillogenesis, iii) calcium binding, iv) hydroxyapatite interaction, v) hydroxyapatite growth
20 inhibition (Orsini et al., 2009). Specifically, Decorin and Biglycan are believed to play a role in the
21 organisation of the collagen matrix during dentinogenesis, are thought to regulate other molecules
22 such as TGF- β 1, influence cell cycle progression and calcium binding (Baker et al., 2009; Embery et al.,
23 2001). Fibromodulin, Osteoadherin and Lumican are believed to play roles in mineralisation of dental
24 tissues (Orsini et al., 2009). Fibromodulin may also play a role in the fibrillogenesis of collagen in
25 predentine (Goldberg et al., 2006). Fragmented SLRPs are also thought to potentially influence
26 signalling to odontoblasts in tertiary dentine deposition (Stankoska et al., 2016).
27
28

29 To date, no experimental PCAs have explored the use of the SLRPs in *in vivo* models. Because their
30 breakdown may help to signal to odontoblasts to begin dentine deposition, fragmented versions of
31 these proteoglycans may be beneficial for consideration of inclusion in a PCA, but as previous studies
32 have shown that dentine deposition can be elicited without the inclusion of these molecules, they are
33 not a priority for consideration. Further work on the roles of these molecules in dentinogenesis is
34 required, including further clarification of their roles in carious and regenerative settings, before they
35 can be considered as reasonable candidates for inclusion in a PCA.
36
37
38

39 Other

40 Adrenomedullin

41 Adrenomedullin (ADM) is a cleaved and processed protein from preproadrenomedullin, and is highly
42 conserved across species and is part of the Calcitonin Gene-related Peptide (CGRP) family (Musson et
43 al., 2010).
44
45
46

47 ADM is thought to upregulate the expression of BMP-2, enhancing odontogenic differentiation of
48 DPSCs (Zhu et al., 2017). This fits with our current understanding of the localisation of ADM to
49 epithelial cells during initial dental development and later to mineralised secretory cells (including
50 odontoblasts) (Musson et al., 2010). ADM has also been shown to be expressed at higher levels in
51 carious over healthy extracted human teeth, and inhibit apoptosis and enhance proliferation of DPSCs
52 *in vitro* (Zhu et al., 2016). ADM is thought to be involved in tertiary dentinogenesis, via p38, eliciting
53 a process of odontoblastic differentiation and mimicking primary dentinogenesis (Simon et al., 2010),
54 though only *in vitro* work currently supports this hypothesis.
55
56
57

58 ADM has only a small body of work exploring the role of this protein in tertiary dentinogenesis. No
59 human or animal studies were found in the literature exploring the use of this bioactive molecule as a
60 PCA. Its effect of inhibiting apoptosis of cells *in vitro*, could raise concerns over the use of this peptide

1
2
3 due to the link of immortal cells to tumour cell theorems. Indeed, the molecule was first identified in
4 a pheochromocytoma (a tumour of adrenal glands) (Kitamura *et al.*, 1993). Considering the current
5 body of work covering ADM, it is not presently a candidate for use in a PCA, though further work
6 eliciting the actions of this molecule in tertiary dentinogenesis may yet yield results to the contrary.
7
8

9 10 Calcitonin

11 Calcitonin is a hypocalcaemic hormone. Calcitonin has been explored as a pulp capping agent as far
12 back as 1982; Smith and Soni used a rat model for comparing pulp capping of $\text{Ca}(\text{OH})_2$ and calcitonin,
13 and they discovered that calcitonin produced a similar response in terms of dentine deposition to
14 $\text{Ca}(\text{OH})_2$ (Smith and Soni, 1982). Similarly, in a dog model, Cullum and Kline found that although
15 calcitonin was able to induce pulp capping dentinogenesis, it did not outperform $\text{Ca}(\text{OH})_2$, though less
16 inflammation was identified in the calcitonin group (Cullum and Kline, 1985). More recently, calcitonin
17 has also been shown to stimulate osteodentine deposition in ferrets (Kline and Yu, 2009), adding to
18 the growing literature supporting this bioactive molecule as a potential candidate for inclusion in a
19 biomimetic PCA. Since the early work on calcitonin, little progress has been made in exploring the best
20 way of utilising this peptide in PCAs.
21
22

23 24 25 Lipids

26 No work has been done to date using lipids sequestered in dentine for pulp capping and these are
27 included solely for completeness.
28

29 Lipids make up a tiny component of dentine matrix (0.26-0.36%)(Goldberg *et al.*, 2008a). Lipids found
30 in dentine include; phosphatidyl inositol, sphingomyelin, phosphatidylcholine,
31 phosphatidylethanolamine, phosphatidyl serine, phosphatidic acid and cardiolipin (Goldberg *et al.*,
32 2011). Of these, sphingomyelin is the most widely explored lipid found in dentine and experimental
33 mouse work has demonstrated that cleaving via neutral sphingomyelinases produce ceramide and
34 phosphocholine, and this process is considered important for normal dentine mineralisation (Aubin *et al.*,
35 2005; Goldberg *et al.*, 2008a). No work has been done to date exploring whether lipids are released
36 from dentine on application of existing PCAs (such as MTA), nor has any work been done exploring
37 whether these lipids are present in reparative dentine or indeed what their role may be in reparative
38 dentine formation. For these reasons, it is difficult to see what role, if any, these molecules may play
39 in being added to a PCA, and as such they are not a priority for consideration for inclusion in a PCA,
40 though further work on their roles in dentine may be of benefit to the wider dental community.
41
42
43

44 45 Enamel Proteins

46 Enamel matrix has long been known to support hard tissue formation in dental structures and have
47 been used for dental pulp capping in animal models (Nakamura *et al.*, 2002), however without
48 knowing the exact composition of the material it is difficult to know or hypothesise the roles individual
49 molecules have on tertiary dentine deposition.
50

51 Amelogenin and ameloblastin are well known enamel proteins, however they are also present in
52 dentine and believed to play a role in odontoblast differentiation (Goldberg *et al.*, 2011), which fits
53 with the potential role these molecules may play in hard tissue formation during pulp capping.
54
55

56 Although amelogenin is not present in healthy, mature adult dentine, predentine or pulp, it has been
57 found to be present in injured and carious dentine at sites of injury and in newly differentiated
58 odontoblasts and is known to be present during primary dentinogenesis (Mitsiadis *et al.*, 2014).
59 Leading on from this work, researchers have explored the potential role that amelogenin may have in
60

1
2
3 dentine hard tissue formation for therapeutic effects, for example, it has been explored successfully
4 for apical closure of root canals in dogs (Mounir et al., 2018). Amelogenin exists as several different
5 isotypes, and each may have differing and varying effects on dentinogenesis. Frasheri et al., 2016 have
6 found that no mineralized tissue is produced when DPSCs are exposed to full length amelogenin, and
7 they suggest that amelogenin may not act as an inducer for dentine production but as an enhancer.
8
9

10 Ameloblastin is thought act as a signalling molecule in primary dentinogenesis and dental-pulp
11 complex regeneration (Spahr et al., 2002) and one study has explored recombinant ameloblastin
12 (without a carrier) as a PCA in rats and out-performed $\text{Ca}(\text{OH})_2$ (Nakamura et al., 2006). The researchers
13 did however find fibrosis in some of the teeth capped, which they feel could be due to 'overdosing'
14 with ameloblastin leading to rapid regenerative activity or related to chronic inflammation caused by
15 the recombinant protein production methods – either way this would need addressing and exploring
16 further before ameloblastin can be considered as a definite candidate for a PCA.
17
18

19 We are beginning to understand the role that some of the enamel proteins may play in reparative
20 dentine formation and as such their potential use for a PCA. The fact that ameloblastin and
21 amelogenin have both successfully produced hard tissue barriers in animal models places these
22 molecules as true potential candidates for a PCA, though we need a better understanding of the
23 potentially dose-dependent results for ameloblastin and to better understand how the different
24 amelogenin isotypes affect dentine deposition.
25
26
27
28

29 Osteocalcin and Calcium Binding Proteins

30 Osteocalcin is expressed in differentiating odontoblasts (Goldberg et al., 2011) and is often used in the
31 literature as a marker for this process.
32
33

34 Osteocalcin is deposited in dentine by odontoblasts, but it is found in bone and cementum too.
35 Although inhibition of osteocalcin is known to inhibit bone production (Ducy et al., 1996), inhibition
36 of osteocalcin (by warfarin) in mice produced no obvious difference in the structure of dentine (Gorter
37 de Vries et al., 1991), and excess osteocalcin did not seem to produce any effects on dentine structure
38 either (Bronckers et al., 1998). The purpose of osteocalcin in dentine is not fully elucidated. Some
39 studies have shown that it plays a role in glucose metabolism, and may therefore be important in
40 facilitating dentine matrix secretion in highly metabolically active odontoblasts (Ferron et al., 2008),
41 though this needs further clarification.
42
43

44 Osteonectin (also known as Secreted Protein, Acidic and Rich in Cysteine/SPARC) is expressed in
45 secretory odontoblasts. Osteonectin contains a calcium binding domain and as such is believed to
46 potentially play a role indirectly in dentine formation, however further work is needed to confirm this
47 (Goldberg et al., 2011).
48

49 Other calcium binding proteins include; calmodulin, calbindin, annexins and nucleobindin.
50 Nucleobindin, calbindin and some of the annexins are believed to play a role in transporting calcium
51 into the ECM during dentine deposition (Goldberg et al., 2011).
52
53

54 Insufficient work has been completed on osteocalcin and the calcium binding proteins found in
55 dentine to fully understand what their role is in dentinogenesis, let alone specifically reparative
56 dentinogenesis. The fact that inhibition of osteocalcin has little to no effect on dentine production
57 suggests that either the role of osteocalcin is too minor to affect dentine production, or that other
58 pathways are able to compensate for inhibition of this molecule. No work has been done on using
59
60

1
2
3 osteocalcin or the calcium binding proteins for pulp capping and as such this section has been included
4 solely for completeness.
5

6 Enzymes

7
8 Matrix Metalloproteinases (MMPs) are calcium dependent, zinc containing enzymes that are
9 sequestered in dentine and play an integral role in development and normal tissue turnover, but also
10 pathological events too.
11

12 The main MMPs identified in dentine are; MMP-8 (a collagenase), MMP-2 and MMP-9 (gelatinases),
13 stromelysin-1 (MMP-3 or proteoglycanase), MMP-14 (MT1-MMP, an MMP-2 activator), MMP-13, and
14 enamelysin (MMP-20) (Chaussain et al., 2013).
15

16 It has been suggested that during carious invasion, these entrapped enzymes may be re-exposed or
17 even activated, leading to increased demineralisation and matrix breakdown (Chaussain et al., 2013).
18 Based upon this, MMPs may be an unusual candidate for inclusion in PCAs, however they may play a
19 role in releasing and activating bioactive molecules from dentine and so have an overall therapeutic
20 effect on dental-pulp complex regeneration (Chaussain et al., 2013), or indeed play a role in activating
21 certain molecules (Chaussain et al., 2009). However, much experimental work has also been
22 completed on the use of MMP inhibitors for slowing down the progression of caries (Gendron et al.,
23 1999; Sulkala et al., 2001; Tjaderhane et al., 1999), highlighting the multi-faceted effects these
24 molecules have in the carious tooth.
25
26
27

28 Based upon our current understanding of these molecules, it may be best to consider these molecules
29 as complicit in carious progression as the literature proving their role in caries (through exploring MMP
30 inhibitors) currently outweighs the evidence that they may be beneficial in dentine regeneration. As
31 such, it is difficult to ascertain the role these enzymes would play in any PCA.
32
33

34 Discussion

35
36 Most *in vivo* work from the literature has explored the use of single proteins as bioactive agents within
37 various carriers. Little *in vivo* work has been done exploring the use of multiple synergistic bioactive
38 molecules for pulp capping. Indeed, the synergistic effect of the different peptides may yield greater
39 tertiary dentinogenesis and better mimic the physiological conditions of tertiary dentinogenesis and
40 from exploring the literature it is clear that the bioactive molecules sequestered in dentine do not
41 work in solo but as a collaborative mixture with specific roles in cell migration and cycling and hard
42 tissue regulation and deposition. Because of this, we should be considering using these molecules as
43 a finely tuned and discrete cocktail of the most essential components for hard tissue formation,
44 without causing pulpal obliteration and facilitating an impervious seal to the pulp.
45
46
47

48 When considering what would be an ideal mix of molecules to use in PCA, careful deliberation of the
49 role of each molecule needs to be taken into account – for example, the inclusion of TGF- β 1 may
50 negate the need for inclusion of SIBLING molecules due to its role in release of DSPP. We would
51 recommend the inclusion of molecules that encourage the migration, proliferation and differentiation
52 of DPSCs in conjunction with a molecule that will inhibit the reparative dentinogenic process, thereby
53 preventing pulpal obliteration. Careful consideration of the spatio-temporal release of these
54 molecules needs to be considered in any PCA design to ensure the correct molecules are released at
55 the correct concentration at the correct time for a suitable period. Preference should be given to
56 molecules reliably capable of producing a dentine hard tissue phenotype over a bone phenotype to
57 give a more impervious dentine bridge. Some molecules are capable of potentiating the effects of
58 others (for example, the role of PDGF on TGF- β 1 (Tabatabaei and Torshabi, 2016)), which may help to
59 accelerate the production of a dentine bridge and may too be considered for inclusion. Until the safety
60

1
2
3 of some molecules is confirmed – particularly those associated with neoplastic properties – these are
4 best avoided for inclusion in a PCA.
5

6
7 When the pulp gets exposed to toxins from caries (for example lactic acid), it becomes inflamed. There
8 is generally a lack of studies exploring the use of bioactive molecules for pulp capping in inflamed, *in*
9 *vivo*, pulp environments. As mentioned earlier in this review, some authors (such as Rutherford and
10 Gu, 2000), have attempted to address this problem. For animal studies to be comparable to clinical
11 work, the experimental setup needs to reflect clinical practice, including; carious teeth/inflamed or
12 infected pulps, isolation of the tooth, suitable wound lavage, haemostasis and isolation control and a
13 suitable restoration. Going forwards, it would be sensible to explore this further with any bioactive
14 molecule considered for inclusion within a pulp cap, to ensure the efficacy of direct pulp capping
15 within an inflamed pulp environment.
16

17
18 From the literature, the peptides with the most supporting evidence are TGF- β 1, and from the BMP
19 group; BMP-2 and BMP-7. More work is required for consideration of the other peptides found
20 sequestered in dentine before they can be considered appropriate candidates for a PCA, with a focus
21 on *in vivo* and clinical work. It may be necessary to compare different bioactive molecules, or even
22 biomimetic PCAs, in the same animal models to compare their efficacy. The work by Hu *et al.*, (Hu
23 *et al.*, 1998) is a stand out study in this instance, where EGF, IGF, basic FGF, TGF- β 1, PDGF, Ca(OH)₂, a
24 collagen carrier control, and a procedure control were compared in the same rat models. Their work
25 demonstrated that TGF- β 1 had significantly better hard and soft tissue healing compared to the other
26 groups.
27

28
29 It is likely that as work continues on the biology of dentine, more bioactive molecules sequestered in
30 dentine will come to light. However, many questions on the release of bioactive molecules in dentine
31 remain unanswered, for example are they released in standard cavity preparation?, how long is
32 release sustained for?, are they chemically or physically bound in dentine (or both)?, and whether
33 caries influences their release dynamics? Understanding this may help in the design of a biomimetic
34 PCA. It is of course entirely possible that not all molecules sequestered in dentine have a role to play
35 in dentine regeneration and may simply be entombed during the process of primary dentinogenesis,
36 and an understanding of all of the molecules sequestered in dentine will help us to better determine
37 which are actually pertinent to tertiary dentine production.
38

39
40 Although some peptides have been explored as PCAs without the use of a carrier, it would be prudent
41 to consider a carrier as an integral part of the creation of a biomimetic PCA. Carriers can allow
42 sustained and timely release of molecules and indeed some have been demonstrated to elicit tertiary
43 dentinogenesis without the need of additional encapsulated factors (Njeh *et al.*, 2016) and some
44 carriers used in the literature are commercially successful PCAs in their own right. The carrier can
45 provide some degree of mechanical and structural support, facilitate the migration of DPSCs, and
46 affect odontogenic differentiation and mineral deposition (Wang *et al.*, 2011). Some of the carriers
47 explored for bioactive molecules have shown to be capable of eliciting tertiary dentine bridges
48 unloaded (ie when they are used as a control without a bioactive molecule added) – for example
49 Goldberg *et al.*, 2001, using gelatin and Koike *et al.*, 2014 using collagen. These studies raise certain
50 questions and ideas – for example, the potential role of a carrier being an active part of the PCA rather
51 than passively releasing and holding the bioactive components, and the possibility that the bioactive
52 molecules sequestered in dentine and subsequently released in cavity preparation may be sufficient
53 for dentine bridge formation without additional exogenous molecules.
54
55

56
57 A short term area of interest may be to explore the use of existing PCAs coupled with added bioactive
58 molecules, as has been explored to some extent already in the literature, to see if we can overcome
59 some of the limiting factors of commercially available PCAs. Another area of potential exploration
60

would be to consider utilising existing materials used for bone regeneration in a pulp capping environment as many of the molecules cross over to see what effect these may have and how these may be modified to facilitate dentine production over bone.

Comparing *in vivo* animal studies is difficult without a clear clinical model comparison. It is important for *in vivo* work to include a suitable control to compare pulp capping efficacy against. Without agreeing upon a clinically standardised control for use in clinical studies, a suitable control will remain contentious. With many different PCA available commercially, it may be advantageous to compare any experimental PCA against multiple different commercially available materials acting as 'controls' for what is currently achievable in the clinic, though experimentally this may be difficult. Indeed, numerous aspects of the management of a direct pulp cap are open to debate, such as the order of the procedures, the agent used for wound lavage, the agent used for haemostasis, the preferred restorative material, and excavation technique (Bjørndal et al., 2019; Chisini et al., 2015; Munir et al., 2020); without consensus upon these, agreeing upon a standardised control for animal work will be difficult.

It has been 13 years since the *in vivo* human work comparing TGF- β 1 to Ca(OH)₂ in sound premolars (Kunarti, 2008). Since then, newer and more effective PCAs have become available and more widely used, which may draw into question whether this is still an avenue that should be explored. With more populations requiring a functional dentition for longer (due to an increased life expectancy), a success rate of 71% at 6 years (Çalışkan and Güneri, 2017) as for MTA for example, may not be considered a good enough outcome for a surgical procedure in an age of burgeoning regenerative medicine. Dentistry, and specifically regenerative endodontics, could lead the field of regenerative medicine providing more predictable, reproducible and successful treatment outcomes for patients. However, we are falling behind our medical colleagues who are pushing further with bone and cartilaginous regeneration. Harnessing the innate power of the dental pulp for regeneration may prove a useful template in broader fields of regenerative medicine, where creation of scaffolds designed around the body's own physiological repair mechanisms may be of benefit. However, considerable optimisation is going to be needed before such a material is ready for clinical trials and commercial marketing.

Conclusion

As there are numerous issues with currently available PCAs, the need for improved physical characteristics and better outcomes when using PCAs is paramount. The utilisation of bioactive molecules in a PCA has the potential to facilitate quicker, more efficient and more successful pulp capping. Tailoring the correct mix of bioactive molecules with the most appropriate carrier is an area that needs greater exploration *in vivo* and the area that we feel requires the most exploration; not only would this potentially provide a better outcome for pulp capping, but it may also elucidate the synergistic roles of many of the sequestered molecules in dentine in tertiary dentinogenesis. Work to date has focused on the formation of a dentine bridge, with less work on the regulation and inhibition of this process once successfully completed, which needs consideration to prevent pulpal obliteration, for example through inclusion of molecules such as SLRPs and SIBLINGS. Successful design of a PCA incorporating a suitable bioactive molecule with a suitable scaffold would allow the pulp's own native stem cells to migrate, differentiate and successfully create a tertiary dentine bridge and the best possible outcome clinically likely involves a mixture of certain molecules.

TGFB-1, BMP-7 and BMP-2 have the most evidential support from the literature with regards to potential pulp capping bioactive molecules, though there are numerous limitations to using the BMP family of molecules and other molecules may prove to be more suited. Considerable optimisation of

1
2
3 the various factors and carrier is required to create the most suitable biomimetic PCA, along with
4 exploration of their use in inflamed pulpal tissue, and this is only achievable through high-quality
5 animal and clinical trials, which to date are lacking in the literature.
6
7
8
9

10 References

11
12 Abd-Elmeguid A, Yu DC, Kline LW, Moqbel R, Vliagoftis H (2012) Dentin matrix protein-1
13 activates dental pulp fibroblasts. *J. Endod.* **38**: 75–80. doi:10.1016/j.joen.2011.10.005.
14 <http://dx.doi.org/10.1016/j.joen.2011.10.005>.

15
16 About I, Bottero MJ, De Denato P, Camps J, Franquin JC, Mitsiadis TA (2000a) Human dentin
17 production in vitro. *Exp. Cell Res.* **258**: 33–41. doi:10.1006/excr.2000.4909.

18
19 About I, Laurent-Maquin D, Lendahl U, Mitsiadis TA (2000b) Nestin expression in embryonic
20 and adult human teeth under normal and pathological conditions. *Am. J. Pathol.* **157**: 287–295.
21 doi:10.1016/S0002-9440(10)64539-7.

22
23 Agamy HA, Bakry NS, Mounir MMF, Avery DR (2004) Comparison of mineral trioxide
24 aggregate and formocresol as pulp-capping agents in pulpotomized primary teeth. *Pediatr. Dent.* **26**:
25 302–309.

26
27 Akdis M, Burgler S, Cramer R, Eiwegger T, Fujita H, Gomez E, Klunker S, Meyer N, O'Mahony
28 L, Palomares O, Rhyner C, Quaked N, Schaffartzik A, Van De Veen W, Zeller S, Zimmermann M, Akdis
29 CA (2011) Interleukins, from 1 to 37, and interferon- γ : Receptors, functions, and roles in diseases. *J.*
30 *Allergy Clin. Immunol.* **127**: 701-721.e70. doi:10.1016/j.jaci.2010.11.050.

31
32 Åkesson M-L, Wärnberg Gerdin E, Söderström U, Lindahl B, Johansson I (2016) Health-
33 related quality of life and prospective caries development. *BMC Oral Health* **16**: 15.
34 doi:10.1186/s12903-016-0166-3. <https://doi.org/10.1186/s12903-016-0166-3>.

35
36 Aksel H, Huang GTJ (2017) Combined Effects of Vascular Endothelial Growth Factor and Bone
37 Morphogenetic Protein 2 on Odonto/Osteogenic Differentiation of Human Dental Pulp Stem Cells
38 In Vitro. *J. Endod.* **43**: 930–935. doi:10.1016/j.joen.2017.01.036.
39 <http://dx.doi.org/10.1016/j.joen.2017.01.036>.

40
41 Al-Hassiny A, Hussaini H, Milne T, Seo B, Rich AM, Friedlander LT (2019) Vascularity and
42 angiogenic signaling in the dentine-pulp complex of immature and mature permanent teeth. *Eur.*
43 *Endod. J.* **4**: 80–85. doi:10.14744/eej.2019.26349.

44
45 Alsanea R, Ravindran S, Fayad MI, Johnson BR, Wenckus CS, Hao J, George A (2011)
46 Biomimetic approach to perforation repair using dental pulp stem cells and dentin matrix protein 1.
47 *J. Endod.* **37**: 1092–1097. doi:10.1016/j.joen.2011.05.019.
48 <http://dx.doi.org/10.1016/j.joen.2011.05.019>.

49
50 Andelin WE, Shabahang S, Wright K, Torabinejad M (2003) Identification of hard tissue after
51 experimental pulp capping using dentin sialoprotein (DSP) as a marker. *J. Endod.* **29**: 646–650.
52 doi:10.1097/00004770-200310000-00008.

53
54 Arany S, Koyota S, Sugiyama T (2009) Nerve growth factor promotes differentiation of
55 odontoblast-like cells. *J. Cell. Biochem.* **106**: 539–545. doi:10.1002/jcb.22006.

56
57 Vander Ark A, Cao J, Li X (2018) TGF- β receptors: In and beyond TGF- β signaling. *Cell. Signal.*
58 **52**: 112–120. doi:10.1016/j.cellsig.2018.09.002.
59
60

1
2
3 Aubin I, Adams CP, Opsahl S, Septier D, Bishop CE, Auge N, Salvayre R, Negre-Salvayre A,
4 Goldberg M, Guénet JL, Poirier C (2005) A deletion in the gene encoding sphingomyelin
5 phosphodiesterase 3 (*Smpd3*) results in osteogenesis and dentinogenesis imperfecta in the mouse.
6 *Nat. Genet.* **37**: 803–805. doi:10.1038/ng1603.

7
8 Austah O, Widbiller M, Tomson PL, Diogenes A (2019) Expression of Neurotrophic Factors in
9 Human Dentin and Their Regulation of Trigeminal Neurite Outgrowth. *J. Endod.* **45**: 414–419.
10 doi:10.1016/j.joen.2018.12.011. <https://doi.org/10.1016/j.joen.2018.12.011>.

11
12 Ayoub A, Gillgrass T (2019) The Clinical Application of Recombinant Human Bone
13 Morphogenetic Protein 7 for Reconstruction of Alveolar Cleft: 10 Years' Follow-Up. *J. Oral Maxillofac.*
14 *Surg.* **77**: 571–581. doi:10.1016/j.joms.2018.08.031.

15
16 Baker SM, Sugars R V., Wendel M, Smith AJ, Waddington RJ, Cooper PR, Sloan AJ (2009) TGF-
17 β /Extracellular matrix interactions in dentin matrix: A role in regulating sequestration and protection
18 of bioactivity. *Calcif. Tissue Int.* **85**: 66–74. doi:10.1007/s00223-009-9248-4.

19
20 Begue-Kirn C, Smith AJ, Lorient M, Kupferle C, Ruch J V., Lesot H (1994) Comparative analysis
21 of TGF β s, BMPs, IGF1, *msxs*, fibronectin, osteonectin and bone sialoprotein gene expression during
22 normal and in vitro-induced odontoblast differentiation. *Int. J. Dev. Biol.* **38**: 405–420.
23 doi:10.1387/ijdb.7848824.

24
25 Begue-Kirn C, Smith AJ, Ruch J V., Wozney JM, Purchio A, Hartmann D, Lesot H (1992) Effects
26 of dentin proteins, transforming growth factor β 1 (TGF β 1) and bone morphogenetic protein 2
27 (BMP2) on the differentiation of odontoblast in vitro. *Int. J. Dev. Biol.* **36**: 491–503.
28 doi:10.1387/ijdb.1295560.

29
30 Behr B, Sorkin M, Lehnhardt M, Renda A, Longaker MT, Quarto N (2012) A comparative
31 analysis of the osteogenic effects of BMP-2, FGF-2, and VEGFA in a calvarial defect model. *Tissue*
32 *Eng. - Part A* **18**: 1079–1086. doi:10.1089/ten.tea.2011.0537.

33
34 Berlanga-Acosta J, Gavilondo-Cowley J, López-Saura P, González-López T, Castro-Santana
35 MD, López-Mola E, Guillén-Nieto G, Herrera-Martinez L (2009) Epidermal growth factor in clinical
36 practice - A review of its biological actions, clinical indications and safety implications. *Int. Wound J.*
37 **6**: 331–346. doi:10.1111/j.1742-481X.2009.00622.x.

38
39 Bjørndal L, Fransson H, Bruun G, Markvart M, Kjældgaard M, Näsman P, Hedenbjörk-Lager A,
40 Dige I, Thordrup M (2017) Randomized Clinical Trials on Deep Carious Lesions: 5-Year Follow-up. *J.*
41 *Dent. Res.* **96**: 747–753. doi:10.1177/0022034517702620.

42
43 Bjørndal L, Simon S, Tomson PL, Duncan HF (2019) Management of deep caries and the
44 exposed pulp. *Int. Endod. J.* **52**: 949–973. doi:10.1111/iej.13128.

45
46 Bleicher F, Richard B, Thivichon-Prince B, Farges JC, Carrouel F (2015) Odontoblasts and
47 Dentin Formation. *Stem Cell Biol. Tissue Eng. Dent. Sci.*: 379–395. doi:10.1016/B978-0-12-397157-
48 9.00034-5.

49
50 Brazil DP, Church RH, Surae S, Godson C, Martin F (2015) BMP signalling: Agony and
51 antagonism in the family. *Trends Cell Biol.* **25**: 249–264. doi:10.1016/j.tcb.2014.12.004.

52
53 Bronckers ALJJ, Price PA, Schrijvers A, Bervoets TJM, Karsenty G (1998) Studies of osteocalcin
54 function in dentin formation in rodent teeth. *Eur. J. Oral Sci.* **106**: 795–807. doi:10.1046/j.0909-
55 8836.1998.eos106306.x.

56
57 Çalışkan MK, Güneri P (2017) Prognostic factors in direct pulp capping with mineral trioxide
58 aggregate or calcium hydroxide: 2- to 6-year follow-up. *Clin. Oral Investig.* **21**: 357–367.
59 doi:10.1007/s00784-016-1798-z.

1
2
3 Calori GM, Colombo M, Bucci M, Mazza EL, Fadigati P, Mazzola S (2015) Clinical effectiveness
4 of Osigraft in long-bones non-unions. *Injury* **46**: S55–S64. doi:10.1016/S0020-1383(15)30056-5.
5 [http://dx.doi.org/10.1016/S0020-1383\(15\)30056-5](http://dx.doi.org/10.1016/S0020-1383(15)30056-5).
6

7 Catón J, Bringas P, Zeichner-David M (2007) Establishment and characterization of an
8 immortalized mouse-derived odontoblast-like cell line to evaluate the effect of insulin-like growth factors
9 on odontoblast differentiation. *J. Cell. Biochem.* **100**: 450–463. doi:10.1002/jcb.21053.
10

11 Chaussain C, Eapen A, Huet E, Floris C, Ravindran S, Hao J, Menashi S, George A (2009)
12 MMP2-cleavage of DMP1 generates a bioactive peptide promoting differentiation of dental pulp
13 stem/progenitor cell. *Eur. Cells Mater.* **18**: 84–95. doi:10.22203/eCM.v018a08.
14 <http://ecmjournal.org/journal/papers/vol018/pdf/v018a08.pdf>.
15

16 Chaussain C, Boukpepsi T, Khaddam M, Tjaderhane L, George A, Menashi S (2013) Dentin
17 matrix degradation by host matrix metalloproteinases: Inhibition and clinical perspectives toward
18 regeneration. *Front. Physiol.* **4 NOV**: 1–8. doi:10.3389/fphys.2013.00308.
19

20 Chen S, Gluhak-Heinrich J, Martinez M, Li T, Wu Y, Chuang HH, Chen L, Dong J, Gay I,
21 MacDougall M (2008) Bone morphogenetic protein 2 mediates dentin sialophosphoprotein
22 expression and odontoblast differentiation via NF- κ B signaling. *J. Biol. Chem.* **283**: 19359–19370.
23 doi:10.1074/jbc.M709492200.
24

25 Chevet-Noël A, Delord M, Bertrand D, Obert L, Lepage D, Pluvy I, Loisel F (2020) RhBMP7 use
26 for treating scaphoid nonunion: 5 cases assessed at 10 years' follow-up. *Hand Surg. Rehabil.*: 1–6.
27 doi:10.1016/j.hansur.2020.06.001.
28

29 Chisini LA, Conde MCM, Correa MB, Dantas RVF, Silva AF, Pappen FG, Demarco FF (2015)
30 Vital pulp therapies in clinical practice: Findings from a survey with dentist in southern Brazil. *Braz.*
31 *Dent. J.* **26**: 566–571. doi:10.1590/0103-6440201300409.
32

33 Cooper PR, Holder MJ, Smith AJ (2014) Inflammation and regeneration in the dentin-pulp
34 complex: A double-edged sword. *J. Endod.* **40**: S46–S51. doi:10.1016/j.joen.2014.01.021.
35 <http://dx.doi.org/10.1016/j.joen.2014.01.021>.
36

37 Cooper PR, Takahashi Y, Graham LW, Simon S, Imazato S, Smith AJ (2010) Inflammation–
38 regeneration interplay in the dentine–pulp complex. *J. Dent.* **38**: 687–697.
39 doi:10.1016/J.JDENT.2010.05.016.
40 <https://www.sciencedirect.com/science/article/pii/S0300571210001259?via%3Dihub>.
41

42 Corinaldesi G, Piersanti L, Piattelli A, Iezzi G, Pieri F, Marchetti C (2013) Augmentation of the
43 floor of the maxillary sinus with recombinant human bone morphogenetic protein-7: A pilot
44 radiological and histological study in humans. *Br. J. Oral Maxillofac. Surg.* **51**: 247–252.
45 doi:10.1016/j.bjoms.2012.06.004. <http://dx.doi.org/10.1016/j.bjoms.2012.06.004>.
46

47 Cullum DR, Kline LW (1985) Pulp response after calcitonin treatment of direct exposures in
48 the dog. *Oral Surg. Oral Med. Oral Pathol.* **60**: 218–223. doi:10.1016/0030-4220(85)90297-x.
49

50 Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S,
51 Gundberg C, Bradley A, Karsenty G (1996) Increased bone formation in osteocalcin-deficient mice.
52 *Nature* **382**: 448–452. doi:10.1038/382448a0.
53

54 Embery G, Hall R, Waddington R, Septier D, Goldberg M (2001) Proteoglycans in
55 Dentinogenesis. *Crit. Rev. Oral Biol. Med.* **12**: 331–349. doi:10.1177/10454411010120040401.
56 <https://doi.org/10.1177/10454411010120040401>.
57

58 Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates β cell and
59 adipocyte gene expression and affects the development of metabolic diseases in wild-type mice.
60

1
2
3 Proc. Natl. Acad. Sci. U. S. A. **105**: 5266–5270. doi:10.1073/pnas.0711119105.
4

5 Frasheri I, Ern C, Diegritz C, Hickel R, Hristov M, Folwaczny M (2016) Full-length amelogenin
6 influences the differentiation of human dental pulp stem cells. *Stem Cell Res. Ther.* **7**: 1–12.
7 doi:10.1186/s13287-015-0269-9. <http://dx.doi.org/10.1186/s13287-015-0269-9>.
8

9 Gendron R, Grenier D, Sorsa T, Mayrand D (1999) Inhibition of the activities of matrix
10 metalloproteinases 2, 8, and 9 by chlorhexidine. *Clin. Diagn. Lab. Immunol.* **6**: 437–439.
11 doi:10.1128/cdli.6.3.437-439.1999.
12

13 Goldberg M, Opsahl S, Aubin I, Septier D, Chaussain-Miller C, Boskey A, Guenet J-L (2008a)
14 Sphingomyelin Degradation is a Key Factor in Dentin and Bone Mineralization: Lessons from the
15 fro/fro Mouse. *J. Dent. Res.* **87**: 9–13. doi:10.1177/154405910808700103.
16 <http://journals.sagepub.com/doi/10.1177/154405910808700103>.
17

18 Goldberg M, Six N, Decup F, Buch D, Soheili Majd E, Lasfargues JJ, Salih E, Stanislawski L
19 (2001) Application of bioactive molecules in pulp-capping situations. *Adv. Dent. Res.* **15**: 91–95.
20 doi:10.1177/08959374010150012401.
21

22 Goldberg M, Farges J, Lacerdapineiro S, Six N, Jegat N, Decup F, Septier D, Carrouel F,
23 Durand S, Chaussainmiller C (2008b) Inflammatory and immunological aspects of dental pulp repair.
24 *Pharmacol. Res.* **58**: 137–147. doi:10.1016/j.phrs.2008.05.013. <http://arxiv.org/abs/1206.2208>.
25

26 Goldberg M, Kulkarni AB, Young M, Boskey A (2011) Dentin: Structure, composition and
27 mineralization. *Front. Biosci. - Elit.* **3 E**: 711–735. doi:10.2741/e281.
28

29 Goldberg M, Septier D, Oldberg Å, Young MF, Ameye LG (2006) Fibromodulin-deficient mice
30 display impaired collagen fibrillogenesis in predentin as well as altered dentin mineralization and
31 enamel formation. *J. Histochem. Cytochem.* **54**: 525–537. doi:10.1369/jhc.5A6650.2005.
32

33 Gorin C, Rochefort GY, Bascetin R, Ying H, Lesieur J, Sadoine J, Beckouche N, Berndt S, Novais
34 A, Lesage M, Hosten B, Vercellino L, Merlet P, Le-Denmat D, Marchiol C, Letourneur D, Nicoletti A,
35 Vital SO, Poliard A, Salmon B, Muller L, Chaussain C, Germain S (2016) Priming Dental Pulp Stem Cells
36 With Fibroblast Growth Factor-2 Increases Angiogenesis of Implanted Tissue-Engineered Constructs
37 Through Hepatocyte Growth Factor and Vascular Endothelial Growth Factor Secretion. *Stem Cells*
38 *Transl. Med.* **5**: 392–404. doi:10.5966/sctm.2015-0166. <http://doi.wiley.com/10.5966/sctm.2015-0166>.
39
40

41 Gorter de Vries I, Wisse E, Williamson MK, Price PA (1991) Effect of warfarin on early rat
42 tooth development. *Calcif. Tissue Int.* **49**: 355–358. doi:10.1007/BF02556259.
43

44 Graham L, Cooper PR, Cassidy N, Nor JE, Sloan AJ, Smith AJ (2006) The effect of calcium
45 hydroxide on solubilisation of bio-active dentine matrix components. *Biomaterials* **27**: 2865–2873.
46 doi:10.1016/j.biomaterials.2005.12.020.
47

48 Hao J, Narayanan K, Ramachandran A, He G, Almushayt A, Evans C, George A (2002)
49 Odontoblast cells immortalized by telomerase produce mineralized dentin-like tissue both in vitro
50 and in vivo. *J. Biol. Chem.* **277**: 19976–19981. doi:10.1074/jbc.M112223200.
51

52 Hargreaves KM, Cohen S (2010) Cohen's Pathways of the Pulp 10th ed. St Louis, Missouri:
53 Mosby.
54

55 Hashemi-Beni B, Khoroushi M, Foroughi MR, Karbasi S, Khademi AA (2017) Tissue
56 engineering: Dentin – pulp complex regeneration approaches (A review). *Tissue Cell.*
57 doi:10.1016/j.tice.2017.07.002.
58

59 He G, Dahl T, Veis A, George A (2003) Dentin matrix protein 1 initiates hydroxyapatite
60

1
2
3 formation in vitro. *Connect. Tissue Res.* **44 Suppl 1**: 240–245.

4
5 Hilton TJ (2009) Keys to Clinical Success with Pulp Capping: A Review of the Literature. *Oper. Dent.* **34**: 615–625. doi:10.2341/09-132-0.

6
7
8 Hinz B (2015) The extracellular matrix and transforming growth factor- β 1 : Tale of a
9 strained relationship. *Matrix Biol.* **47**: 54–65. doi:10.1016/j.matbio.2015.05.006.
10 <http://dx.doi.org/10.1016/j.matbio.2015.05.006>.

11
12 Hong KS, Kim EC, Bang SH, Chung CH, Lee Y Il, Hyun JK, Lee HH, Jang JH, Kim T Il, Kim HW
13 (2010) Bone regeneration by bioactive hybrid membrane containing FGF2 within rat calvarium. *J.*
14 *Biomed. Mater. Res. - Part A* **94**: 1187–1194. doi:10.1002/jbm.a.32799.

15
16 Howard C, Murray PE, Namerow KN (2010) Dental pulp stem cell migration. *J. Endod.* **36**:
17 1963–1966. doi:10.1016/j.joen.2010.08.046. <http://dx.doi.org/10.1016/j.joen.2010.08.046>.

18
19 Hu CC, Zhang C, Qian Q, Tatum NB (1998) Reparative dentin formation in rat molars after
20 direct pulp capping with growth factors. *J. Endod.* **24**: 744–751. doi:10.1016/S0099-2399(98)80166-
21 0.

22
23 Hu JC-C, Zhang C, Yun S-S, Qian Q, Ranly DM (1997) Platelet-Derived Growth Factor-BB and
24 Epidermal Growth Factor as Pulp Capping Medicaments in Rat Incisors. *J. hard tissue Biol.* **6**: 121–
25 129.

26
27 Iohara K, Nakashima M, Ito M, Ishikawa M, Nakasima A, Akamine A (2004) Dentin
28 regeneration by dental pulp stem cell therapy with recombinant human bone morphogenetic
29 protein 2. *J. Dent. Res.* **83**: 590–595. doi:10.1177/154405910408300802.

30
31 Iohara K, Murakami M, Takeuchi N, Osako Y, Ito M, Ishizaka R, Utunomiya S, Nakamura H,
32 Matsushita K, Nakashima M (2013) A Novel Combinatorial Therapy With Pulp Stem Cells and
33 Granulocyte Colony-Stimulating Factor for Total Pulp Regeneration. *Stem Cells Transl. Med.* **2**: 521–
34 533. doi:10.5966/sctm.2012-0132. <https://doi.org/10.5966/sctm.2012-0132>.

35
36 Ishimatsu H, Kitamura C, Morotomi T, Tabata Y, Nishihara T, Chen KK, Terashita M (2009)
37 Formation of Dentinal Bridge on Surface of Regenerated Dental Pulp in Dentin Defects by Controlled
38 Release of Fibroblast Growth Factor-2 From Gelatin Hydrogels. *J. Endod.* **35**: 858–865.
39 doi:10.1016/j.joen.2009.03.049. <http://dx.doi.org/10.1016/j.joen.2009.03.049>.

40
41 Kigami R, Sato S, Tsuchiya N, Yoshimakai T, Arai Y, Ito K (2013) FGF-2 angiogenesis in bone
42 regeneration within critical-sized bone defects in rat calvaria. *Implant Dent.* **22**: 422–427.
43 doi:10.1097/ID.0b013e31829d19f0.

44
45 Kikuchi N, Kitamura C, Morotomi T, Inuyama Y, Ishimatsu H, Tabata Y, Nishihara T, Terashita
46 M (2007) Formation of Dentin-like Particles in Dentin Defects above Exposed Pulp by Controlled
47 Release of Fibroblast Growth Factor 2 from Gelatin Hydrogels. *J. Endod.* **33**: 1198–1202.
48 doi:10.1016/j.joen.2007.07.025.

49
50 Kim J-H, Hong J-B, Lim B-S, Cho B-H (2009) Histological evaluation of direct pulp capping with
51 DSP-derived synthetic peptide in beagle dog. *J. Korean Acad. Conserv. Dent.* **34**: 120.
52 doi:10.5395/jkacd.2009.34.2.120.

53
54 Kim SY, Lee SM, Lee JH (2019) Initial Cytotoxicity of Mineral Trioxide Aggregate (MTA) during
55 Setting on Human Mesenchymal Stem Cells. *Adv. Mater. Sci. Eng.* **2019**. doi:10.1155/2019/2365104.

56
57 Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE (2004) Local
58 Delivery of Marrow-Derived Stromal Cells Augments Collateral Perfusion Through Paracrine
59 Mechanisms. *Circulation* **109**: 1543–1549. doi:10.1161/01.CIR.0000124062.31102.57.
60

1
2
3 Kitamura, K, Kangawa, K, Kawamoto, M, Ichiki, Y, Nakamura, S, Matsuo, H, Eto T (1993)
4 Reprint of "Adrenomedullin: A Novel Hypotensive Peptide Isolated from Human
5 Pheochromocytoma." *Biochem. Biophys. Res. Commun.* **192**: 553–560.
6 doi:10.1016/j.bbrc.2012.08.022. <https://linkinghub.elsevier.com/retrieve/pii/S0006291X12015197>.
7

8 Kline LW, Yu DC (2009) Effects of Calcitonin, Calcitonin Gene-Related Peptide, Human
9 Recombinant Bone Morphogenetic Protein-2, and Parathyroid Hormone-Related Protein on
10 Endodontically Treated Ferret Canines. *J. Endod.* **35**: 866–869. doi:10.1016/j.joen.2009.03.045.
11 <http://dx.doi.org/10.1016/j.joen.2009.03.045>.
12

13 Ko H, Yang W, Park K, Kim M (2010) Cytotoxicity of mineral trioxide aggregate (MTA) and
14 bone morphogenetic protein 2 (BMP-2) and response of rat pulp to MTA and BMP-2. *Oral Surgery,*
15 *Oral Med. Oral Pathol. Oral Radiol. Endodontology* **109**: e103–e108.
16 doi:10.1016/j.tripleo.2010.01.030. <http://dx.doi.org/10.1016/j.tripleo.2010.01.030>.
17

18 Koike T, Polan MAA, Izumikawa M, Saito T (2014) Induction of reparative dentin formation
19 on exposed dental pulp by dentin phosphophoryn/collagen composite. *Biomed Res. Int.* **2014**.
20 doi:10.1155/2014/745139.
21

22 Kunarti S (2008) Pulp tissue inflammation and angiogenesis after pulp capping with
23 transforming growth factor β 1. *Dent. J. (Majalah Kedokt. Gigi)* **41**: 88.
24 doi:10.20473/j.djmk.v41.i2.p88-90.
25

26 Li F, Liu X, Zhao S, Wu H, Xu HHK (2014) Porous chitosan bilayer membrane containing TGF-
27 β 1 loaded microspheres for pulp capping and reparative dentin formation in a dog model. *Dent.*
28 *Mater.* **30**: 172–181. doi:10.1016/j.dental.2013.11.005.
29 <http://dx.doi.org/10.1016/j.dental.2013.11.005>.
30

31 Li L, Wang Z (2016) PDGF-BB, NGF and BDNF enhance pulp-like tissue regeneration: Via cell
32 homing. *RSC Adv.* **6**: 109519–109527. doi:10.1039/c6ra20290j.
33

34 Li W, Chen L, Chen Z, Wu L, Feng J, Wang F, Shoff L, Li X, Donly KJ, MacDougall M, Chen S
35 (2017) Dentin sialoprotein facilitates dental mesenchymal cell differentiation and dentin formation.
36 *Sci. Rep.* **7**: 1–18. doi:10.1038/s41598-017-00339-w. <http://dx.doi.org/10.1038/s41598-017-00339-w>.
37
38

39 Lim W, Bae H, Bazer FW, Song G (2017) Stimulatory effects of fibroblast growth factor 2 on
40 proliferation and migration of uterine luminal epithelial cells during early pregnancy. *Biol. Reprod.*
41 **96**: 185–198. doi:10.1095/biolreprod.116.142331.
42

43 Linsuwant P, Wimonstuthikul K, Pothimoke U, Santiwong B (2017) Treatment Outcomes
44 of Mineral Trioxide Aggregate Pulpotomy in Vital Permanent Teeth with Carious Pulp Exposure: The
45 Retrospective Study. *J. Endod.* **43**: 225–230. doi:10.1016/j.joen.2016.10.027.
46 <http://dx.doi.org/10.1016/j.joen.2016.10.027>.
47

48 Lipski M, Nowicka A, Kot K, Postek-Stefańska L, Wysoczańska-Jankowicz I, Borkowski L,
49 Andersz P, Jarząbek A, Grocholewicz K, Sobolewska E, Woźniak K, Drożdżik A (2018) Factors affecting
50 the outcomes of direct pulp capping using Biodentine. *Clin. Oral Investig.* **22**: 2021–2029.
51 doi:10.1007/s00784-017-2296-7.
52

53 Listik E, Azevedo Marques Gaschler J, Matias M, Neuppmann Feres MF, Toma L, Raphaelli
54 Nahás-Scocate AC (2019) Proteoglycans and dental biology: the first review. *Carbohydr. Polym.* **225**.
55 doi:10.1016/j.carbpol.2019.115199.
56

57 Listl S, Galloway J, Mossey PA, Marcenes W (2015) Global economic impact of dental
58 diseases. *In J. Dent. Res.* doi:10.1177/0022034515602879.
59
60

1
2
3 Lovschall H, Fejerskov O, Flyvbjerg A (2001) Pulp-capping with recombinant human insulin-
4 like growth factor I (rhIGF-I) in rat molars. *Adv. Dent. Res.* **15**: 108–112.
5 doi:10.1177/08959374010150010301.
6

7 Lv T, Wu Y, Mu C, Liu G, Yan M, Xu X, Wu H, Du J, Yu J, Mu J (2016) Insulin-like growth factor
8 1 promotes the proliferation and committed differentiation of human dental pulp stem cells through
9 MAPK pathways. *Arch. Oral Biol.* **72**: 116–123. doi:10.1016/j.archoralbio.2016.08.011.
10 http://dx.doi.org/10.1016/j.archoralbio.2016.08.011.
11

12 Matsumura S, Quispe-Salcedo A, Schiller CM, Shin JS, Locke BM, Yakar S, Shimizu E (2017)
13 IGF-1 Mediates EphrinB1 Activation in Regulating Tertiary Dentin Formation. *J. Dent. Res.* **96**: 1153–
14 1161. doi:10.1177/0022034517708572.
15

16 Matsushita K, Motani R, Sakuta T, Yamaguchi N, Koga T, Matsuo K, Nagaoka S, Abeyama K,
17 Maruyama I, Torii M (2000) The role of vascular endothelial growth factor in human dental pulp
18 cells: Induction of chemotaxis, proliferation, and differentiation and activation of the AP-1-
19 dependent signaling pathway. *J. Dent. Res.* **79**: 1596–1603. doi:10.1177/00220345000790081201.
20

21 McCoy RJ, Widaa A, Watters KM, Wuerstle M, Stallings RL, Duffy GP, O'Brien FJ (2013)
22 Orchestrating osteogenic differentiation of mesenchymal stem cells - Identification of placental
23 growth factor as a mechanosensitive gene with a pro-osteogenic role. *Stem Cells* **31**: 2420–2431.
24 doi:10.1002/stem.1482.
25

26 McLachlan JL, Smith AJ, Sloan AJ, Cooper PR (2003) Gene expression analysis in cells of the
27 dentine-pulp complex in healthy and carious teeth. *Arch. Oral Biol.* doi:10.1016/S0003-
28 9969(03)00003-7.
29

30 Mente J, Hufnagel S, Leo M, Michel A, Gehrig H, Panagidis D, Saure D, Pfefferle T (2014)
31 Treatment outcome of mineral trioxide aggregate or calcium hydroxide direct pulp capping: Long-
32 term results. *J. Endod.* **40**: 1746–1751. doi:10.1016/j.joen.2014.07.019.
33 http://dx.doi.org/10.1016/j.joen.2014.07.019.
34

35 Mitsiadis TA, Filatova A, Papaccio G, Goldberg M, About I, Papagerakis P (2014) Distribution
36 of the amelogenin protein in developing, injured and carious human teeth. *Front. Physiol.* **5**: 1–8.
37 doi:10.3389/fphys.2014.00477.
38

39 Mounir MMF, Farsi JMA, Alhazzazi TY, Matar MA, El-Housseiny AA (2018) Characterization of
40 the apical bridge barrier formed following amelogenin apexification. *BMC Oral Health* **18**: 1–8.
41 doi:10.1186/s12903-018-0641-0.
42

43 Munir A, Zehnder M, Rechenberg D-K (2020) Wound Lavage in Studies on Vital Pulp Therapy
44 of Permanent Teeth with Carious Exposures: A Qualitative Systematic Review. *J. Clin. Med.* **9**: 984.
45 doi:10.3390/jcm9040984.
46

47 Murray PE, Lumley PJ, Hafez AA, Cox CF, Smith AJ (2002) Preserving the vital pulp in
48 operative dentistry: 4. Factors influencing successful pulp capping. *Dent. Update* **29**.
49 doi:10.12968/denu.2002.29.5.225.
50

51 Musson DS, McLachlan JL, Sloan AJ, Smith AJ, Cooper PR (2010) Adrenomedullin is expressed
52 during rodent dental tissue development and promotes cell growth and mineralization. *Biol. Cell*
53 **102**: 145–157. doi:10.1042/bc20090122.
54

55 Nakamura Y, Hammarström L, Matsumoto K, Lyngstadaas SP (2002) The induction of
56 reparative dentine by enamel proteins. *Int. Endod. J.* **35**: 407–417. doi:10.1046/j.1365-
57 2591.2002.00556.x.
58

59 Nakamura Y, Slaby I, Spahr A, Pezeshki G, Matsumoto K, Lyngstadaas SP (2006) Ameloblastin
60

1
2
3 fusion protein enhances pulpal healing and dentin formation in porcine teeth. *Calcif. Tissue Int.* **78**:
4 278–284. doi:10.1007/s00223-005-0144-2.

5
6 Nakashima M (1992) The effects of growth factors on DNA synthesis, proteoglycan synthesis
7 and alkaline phosphatase activity in bovine dental pulp cells. *Arch. Oral Biol.* **37**: 231–236.
8 doi:10.1016/0003-9969(92)90093-N.

9
10 Nakashima M (1994a) Induction of dentine in amputated pulp of dogs by recombinant
11 human bone morphogenetic proteins-2 and -4 with collagen matrix. *Arch. Oral Biol.* **39**: 1085–1089.
12 doi:10.1016/0003-9969(94)90062-0.

13
14 Nakashima M (1994b) Induction of Dentin Formation on Canine Amputated Pulp by
15 Recombinant Human Bone Morphogenetic Proteins (BMP)-2 and -4. *J. Dent. Res.* **73**: 1515–1522.
16 doi:10.1177/00220345940730090601.

17
18 Nakashima M, Iohara K (2017) Recent Progress in Translation from Bench to a Pilot Clinical
19 Study on Total Pulp Regeneration. *J. Endod.* **43**: S82–S86. doi:10.1016/j.joen.2017.06.014.
20 <http://dx.doi.org/10.1016/j.joen.2017.06.014>.

21
22 Nakashima M, Reddi AH (2003) The application of bone morphogenetic proteins to dental
23 tissue engineering. *Nat. Biotechnol.* **21**: 1025–1032. doi:10.1038/nbt864.

24
25 Narayanan K, Srinivas R, Ramachandran A, Hao J, Quinn B, George A (2001) Differentiation of
26 embryonic mesenchymal cells to odontoblast-like cells by overexpression of dentin matrix protein 1.
27 *Proc. Natl. Acad. Sci. U. S. A.* **98**: 4516–4521. doi:10.1073/pnas.081075198.

28
29 Niwa T, Yamakoshi Y, Yamazaki H, Karakida T, Chiba R, Hu JCC, Nagano T, Yamamoto R,
30 Simmer JP, Margolis HC, Gomi K (2018) The dynamics of TGF- β in dental pulp, odontoblasts and
31 dentin. *Sci. Rep.* **8**: 1–14. doi:10.1038/s41598-018-22823-7. [http://dx.doi.org/10.1038/s41598-018-](http://dx.doi.org/10.1038/s41598-018-22823-7)
32 [22823-7](http://dx.doi.org/10.1038/s41598-018-22823-7).

33
34 Njeh A, Uzunoğlu E, Ardila-Osorio H, Simon S, Berdal A, Kellermann O, Goldberg M (2016)
35 Reactionary and reparative dentin formation after pulp capping: Hydrogel vs. Dycal. *Evidence-Based*
36 *Endod.* **1**: 3. doi:10.1186/s41121-016-0003-9. <https://doi.org/10.1186/s41121-016-0003-9>.

37
38 Ohnishi T, Suwa M, Oyama T, Arakaki N, Torii M, Daikuhara Y (2000) Prostaglandin E2
39 predominantly induces production of hepatocyte growth factor/scatter factor in human dental pulp
40 in acute inflammation. *J. Dent. Res.* **79**: 748–755. doi:10.1177/00220345000790020801.

41
42 Ohnishi T, Daikuhara Y (2003) Hepatocyte growth factor/scatter factor in development,
43 inflammation and carcinogenesis: Its expression and role in oral tissues. *Arch. Oral Biol.* **48**: 797–804.
44 doi:10.1016/S0003-9969(03)00180-8.

45
46 Oliva-Rodríguez R, Pérez-Urizar J, Dibildox-Alvarado E, Martínez-Saldaña MC, Avelar-
47 González FJ, Flores-Reyes H, Pozos-Guillén ADJ, Guerrero-Barrera AL (2011) Design of a controlled
48 release system of OP-1 and TGF- β 1 based in microparticles of sodium alginate and release
49 characterization by HPLC-UV. *Vitr. Cell. Dev. Biol. - Anim.* **47**: 681–688. doi:10.1007/s11626-011-
50 9459-7.

51
52 Orsini G, Ruggeri A, Mazzoni A, Nato F, Manzoli L, Putignano A, Di Lenarda R, Tjäderhane L,
53 Breschi L (2009) A review of the nature, role, and function of dentin non-collagenous proteins. Part
54 1: proteoglycans and glycoproteins. *Endod. Top.* **21**: 1–18. doi:10.1111/j.1601-1546.2012.00270.x.

55
56 Pan S, Dangaria S, Gopinathan G, Yan X, Lu X, Kolokythas A, Niu Y, Luan X (2013) SCF
57 Promotes Dental Pulp Progenitor Migration, Neovascularization, and Collagen Remodeling -
58 Potential Applications as a Homing Factor in Dental Pulp Regeneration. *Stem Cell Rev. Reports* **9**:
59 655–667. doi:10.1007/s12015-013-9442-7.

1
2
3 Paula AB, Laranjo M, Marto CM, Paulo S, Abrantes AM, Casalta-Lopes J, Marques-Ferreira M,
4 Botelho MF, Carrilho E (2018) Direct Pulp Capping: What is the Most Effective Therapy?—Systematic
5 Review and Meta-Analysis. *J. Evid. Based. Dent. Pract.* **18**: 298–314.
6 doi:10.1016/j.jebdp.2018.02.002. <https://doi.org/10.1016/j.jebdp.2018.02.002>.

8 Qu T, Jing J, Ren Y, Ma C, Feng JQ, Yu Q, Liu X (2015) Complete pulpodentin complex
9 regeneration by modulating the stiffness of biomimetic matrix. *Acta Biomater.* **16**: 60–70.
10 doi:10.1016/j.ACTBIO.2015.01.029.
11 <https://www.sciencedirect.com/science/article/pii/S1742706115000392?via%3Dihub>.

13 Qureshi A, Soujanya E, Kumar N, Kumar P, Hivarao S (2014) Recent advances in pulp capping
14 materials: An overview. *J. Clin. Diagnostic Res.* **8**: 316–321. doi:10.7860/JCDR/2014/7719.3980.

16 Rambhia KJ, Ma PX (2015) Controlled drug release for tissue engineering. *J. Control. Release*
17 **219**: 119–128. doi:10.1016/j.jconrel.2015.08.049.
18 <https://www.ncbi.nlm.nih.gov/pubmed/26325405>.

20 Ritter A V. (2007) Direct Pulp-Capping Performed by Dental Students has a Success Rate
21 Close to 60%. Direct Capping of Carious Pulp Exposures is Significantly Less Successful (33%) than
22 Direct Capping of Mechanical Pulp Exposures (92%). *J. Evid. Based. Dent. Pract.* **7**: 165–166.
23 doi:10.1016/j.jebdp.2007.09.001.

25 Roberts-Clark DJ, Smith AJ (2000) Angiogenic growth factors in human dentine matrix. *Arch.*
26 *Oral Biol.* **45**: 1013–1016. doi:10.1016/S0003-9969(00)00075-3.

28 da Rosa WLO, Piva E, da Silva AF (2018a) Disclosing the physiology of pulp tissue for vital
29 pulp therapy. *Int. Endod. J.* **51**: 829–846. doi:10.1111/iej.12906.

31 da Rosa WLO, Cocco AR, Silva TM d., Mesquita LC, Galarça AD, Silva AF d., Piva E (2018b)
32 Current trends and future perspectives of dental pulp capping materials: A systematic review. *J.*
33 *Biomed. Mater. Res. - Part B Appl. Biomater.* **106**: 1358–1368. doi:10.1002/jbm.b.33934.

35 Ruangsawasdi N, Zehnder M, Patcas R, Ghayor C, Siegenthaler B, Gjoksi B, Weber FE (2017)
36 Effects of stem cell factor on cell homing during functional pulp regeneration in human immature
37 teeth. *Tissue Eng. - Part A* **23**: 115–123. doi:10.1089/ten.tea.2016.0227.

39 Rutherford RB, Gu K (2000) Treatment of inflamed ferret dental pulps with recombinant
40 bone morphogenetic protein-7. *Eur. J. Oral Sci.* **108**: 202–206. doi:10.1034/j.1600-
41 0722.2000.108003202.x.

43 Rutherford RB, Spångberg L, Tucker M, Rueger D, Charette M (1994) The time-course of the
44 induction of reparative dentine formation in monkeys by recombinant human osteogenic protein-1.
45 *Arch. Oral Biol.* **39**: 833–838. doi:10.1016/0003-9969(94)90014-0.

47 Rutherford RB, Wahle J, Tucker M, Rueger D, Charette M (1993) Induction of reparative
48 dentine formation in monkeys by recombinant human osteogenic Protein-1. *Arch. Oral Biol.* **38**: 571–
49 576. doi:10.1016/0003-9969(93)90121-2.

51 Rutherford RB (2001) Short communication BMP-7 gene transfer to inflamed ferret dental
52 pulps **7**: 422–424.

54 Sailhan F, Gleyzolle B, Parot R, Guerini H, Viguier E (2010) Rh-BMP-2 in distraction
55 osteogenesis: Dose effect and premature consolidation. *Injury* **41**: 680–686.
56 doi:10.1016/j.injury.2009.10.010.

58 Saito K, Nakatomi M, Ida-Yonemochi H, Ohshima H (2016) Osteopontin Is Essential for Type I
59 Collagen Secretion in Reparative Dentin. *J. Dent. Res.* **95**: 1034–1041.

1
2
3 doi:10.1177/0022034516645333.

4
5 Saito K, Nakatomi M, Ida-Yonemochi H, Kenmotsu S ichi, Ohshima H (2011) The expression
6 of GM-CSF and osteopontin in immunocompetent cells precedes the odontoblast differentiation
7 following allogenic tooth transplantation in mice. *J. Histochem. Cytochem.* **59**: 518–529.
8 doi:10.1369/0022155411403314.

9
10 Schmalz G, Widbiller M, Galler KM (2017) Signaling Molecules and Pulp Regeneration. *J.*
11 *Endod.* **43**: S7–S11. doi:10.1016/j.joen.2017.06.003. <http://dx.doi.org/10.1016/j.joen.2017.06.003>.

12
13 Simon S, Smith AJ, Berdal A, Lumley PJ, Cooper PR (2010) The MAP Kinase Pathway Is
14 Involved in Odontoblast Stimulation via p38 Phosphorylation. *J. Endod.* **36**: 256–259.
15 doi:10.1016/j.joen.2009.09.019. <http://dx.doi.org/10.1016/j.joen.2009.09.019>.

16
17 Six N, Decup F, Lasfargues JJ, Salih E, Goldberg M (2002a) Osteogenic proteins (bone
18 sialoprotein and bone morphogenetic protein-7) and dental pulp mineralization. *J. Mater. Sci. Mater.*
19 *Med.* **13**: 225–232. doi:10.1023/A:1013846516693.

20
21 Six N, Septier D, Chaussain-Miller C, Blacher R, DenBesten P, Goldberg M (2007) Dentonin, a
22 MEPE fragment initiates pulp-healing response to injury. *J. Dent. Res.* **86**: 780–785.
23 doi:10.1177/154405910708600818.

24
25 Six N, Lasfargues JJ, Goldberg M (2002b) Differential repair responses in the coronal and
26 radicular areas of the exposed rat molar pulp induced by recombinant human bone morphogenetic
27 protein 7 (osteogenic protein 1). *Arch. Oral Biol.* **47**: 177–187. doi:10.1016/S0003-9969(01)00100-5.

28
29 Sloan AJ (2015) Biology of the Dentin-Pulp Complex. In *Stem Cell Biol. Tissue Eng. Dent. Sci.*,
30 371–378. Elsevier. doi:10.1016/B978-0-12-397157-9.00033-3. <http://dx.doi.org/10.1016/B978-0-12-397157-9.00033-3>.

31
32
33 Smith AJ, Scheven BA, Takahashi Y, Ferracane JL, Shelton RM, Cooper PR (2012) Dentine as a
34 bioactive extracellular matrix. *Arch. Oral Biol.* **57**: 109–121. doi:10.1016/j.archoralbio.2011.07.008.
35 <http://dx.doi.org/10.1016/j.archoralbio.2011.07.008>.

36
37 Smith AJ (2003) Vitality of the dentin-pulp complex in health and disease: growth factors as
38 key mediators. *J. Dent. Educ.* **67**: 678. <http://www.jdentaled.org/content/67/6/678.abstract>.

39
40 Smith AJ, Duncan HF, Diogenes A, Simon S, Cooper PR (2016) Exploiting the Bioactive
41 Properties of the Dentin-Pulp Complex in Regenerative Endodontics. *J. Endod.* **42**: 47–56.
42 doi:10.1016/j.joen.2015.10.019. <http://dx.doi.org/10.1016/j.joen.2015.10.019>.

43
44 Smith HS, Soni NN (1982) Histologic study of pulp capping in rat molars using calcitonin. *Oral*
45 *Surg. Oral Med. Oral Pathol.* **53**: 311–317. doi:10.1016/0030-4220(82)90308-5.

46
47 Spahr A, Lyngstadaas SP, Slaby I, Haller B, Boeckh C, Tsoulfidou F, Hammarstrom L (2002)
48 Expression of amelin and trauma-induced dentin formation. *Clin. Oral Investig.* **6**: 51–57.
49 doi:10.1007/s00784-001-0139-y.

50
51 Stankoska K, Sarram L, Smith S, Bedran-Russo AK, Little CB, Swain M V., Bertassoni LE (2016)
52 Immunolocalization and distribution of proteoglycans in carious dentine. *Aust. Dent. J.* **61**: 288–297.
53 doi:10.1111/adj.12376.

54
55 Stanley HR, Pameijer CH (1997) Dentistry's friend: calcium hydroxide. *Oper. Dent.* **22**: 1–3.
56 <http://europepmc.org/abstract/MED/9227121>.

57
58 Sulkala M, Wahlgren J, Larmas M, Sorsa T, Teronen O, Salo T, Tjäderhane L (2001) The Effects
59 of MMP Inhibitors on Human Salivary MMP Activity and Caries Progression in Rats. *J. Dent. Res.* **80**:
60 1545–1549. doi:10.1177/00220345010800061301.

1
2
3 <http://journals.sagepub.com/doi/10.1177/00220345010800061301>.

4
5 Suzuki T, Lee CH, Chen M, Zhao W, Fu SY, Qi JJ, Chotkowski G, Eisig SB, Wong A, Mao JJ
6 (2011) Induced migration of dental pulp stem cells for in vivo pulp regeneration. *J. Dent. Res.* **90**:
7 1013–1018. doi:10.1177/0022034511408426.

8
9 Tabatabaei FS, Torshabi M (2016) Effects of Non-Collagenous Proteins, TGF- β 1, and PDGF-BB
10 on Viability and Proliferation of Dental Pulp Stem Cells. *J. Oral Maxillofac. Res.* **7**: 1–9.
11 doi:10.5037/jomr.2016.7104.

12
13 Takeuchi N, Hayashi Y, Murakami M, Alvarez FJ, Horibe H, Iohara K, Nakata K, Nakamura H,
14 Nakashima M (2015) Similar in vitro effects and pulp regeneration in ectopic tooth transplantation
15 by basic fibroblast growth factor and granulocyte-colony stimulating factor. *Oral Dis.* **21**: 113–122.
16 doi:10.1111/odi.12227.

17
18 Teng CF, Jeng L Bin, Shyu WC (2018) Role of Insulin-like Growth Factor 1 Receptor Signaling
19 in Stem Cell Stemness and Therapeutic Efficacy. *Cell Transplant.* **27**: 1313–1319.
20 doi:10.1177/0963689718779777.

21
22 Tjaderhane L, Sulkala M, Sorsa T, Teronen O, Larmas M, Salo T (1999) The Effect of MMP
23 Inhibitor Metastat on Fissure Caries Progression in Rats. *Ann. N. Y. Acad. Sci.* **878**: 686–688.
24 doi:10.1111/j.1749-6632.1999.tb07762.x. [http://doi.wiley.com/10.1111/j.1749-](http://doi.wiley.com/10.1111/j.1749-6632.1999.tb07762.x)
25 [6632.1999.tb07762.x](http://doi.wiley.com/10.1111/j.1749-6632.1999.tb07762.x).

26
27 Tomson PL, Lumley PJ, Smith AJ, Cooper PR (2017) Growth factor release from dentine
28 matrix by pulp-capping agents promotes pulp tissue repair-associated events. *Int. Endod. J.* **50**: 281–
29 292. doi:10.1111/iej.12624.

30
31 Tomson PL, Lumley PJ, Alexander MY, Smith AJ, Cooper PR (2013) Hepatocyte growth factor
32 is sequestered in dentine matrix and promotes regeneration-associated events in dental pulp cells.
33 *Cytokine* **61**: 622–629. doi:10.1016/j.cyto.2012.11.009.
34 <http://dx.doi.org/10.1016/j.cyto.2012.11.009>.

35
36 Trapnell BC, Abe S (2006) Colony Stimulating Factors. *Encycl. Respir. Med. Four-Volume Set*:
37 540–546. doi:10.1016/B0-12-370879-6/00093-4.

38
39 Tüzüner T, Alacam A, Altunbas DA, Gokdogan FG, Gundogdu E (2012) Clinical and
40 radiographic outcomes of direct pulp capping therapy in primary molar teeth following haemostasis
41 with various antiseptics: a randomised controlled trial. *Eur. J. Paediatr. Dent.* **13**: 289–292.

42
43 Tziafas D, Alvanou A, Papadimitriou S, Gasic J, Komnenou A (1998) Effects of recombinant
44 basic fibroblast growth factor, insulin-like growth factor-II and transforming growth factor- β 1 on dog
45 dental pulp cells in vivo. *Arch. Oral Biol.* **43**: 431–444. doi:10.1016/S0003-9969(98)00026-0.

46
47 Tziafas D, Kodonas K, Gogos C, Tziafa C, Papadimitriou S (2017) Dentine-pulp tissue
48 engineering in miniature swine teeth by set calcium silicate containing bioactive molecules. *Arch.*
49 *Oral Biol.* **73**: 230–236. doi:10.1016/j.archoralbio.2016.10.023.
50 <http://dx.doi.org/10.1016/j.archoralbio.2016.10.023>.

51
52 Vincentelli AF, Szadkowski M, Vardon D, Litrico S, Fuentès S, Steib JP, Le Huec JC, Huppert J,
53 Dubois G, Lenoir T, Sailhan F, Passuti N (2019) rhBMP-2 (Recombinant Human Bone Morphogenetic
54 Protein-2) in real world spine surgery. A phase IV, National, multicentre, retrospective study
55 collecting data from patient medical files in French spinal centres. *Orthop. Traumatol. Surg. Res.* **105**:
56 1157–1163. doi:10.1016/j.otsr.2019.04.023.

57
58 Wang J, Liu X, Jin X, Ma H, Hu J, Ni L, Ma PX (2010) The odontogenic differentiation of human
59 dental pulp stem cells on nanofibrous poly(l-lactic acid) scaffolds in vitro and in vivo. *Acta Biomater.*

1
2
3 **6:** 3856–3863. doi:10.1016/j.actbio.2010.04.009. <http://dx.doi.org/10.1016/j.actbio.2010.04.009>.

4
5 Wang J, Ma H, Jin X, Hu J, Liu X, Ni L, Ma PX (2011) The effect of scaffold architecture on
6 odontogenic differentiation of human dental pulp stem cells. *Biomaterials* **32**: 7822–7830.
7 doi:10.1016/j.biomaterials.2011.04.034.

8
9 World Health Organisation (2018) Oral Health. [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/oral-health)
10 [sheets/detail/oral-health](https://www.who.int/news-room/fact-sheets/detail/oral-health).

11
12 Wu S, Zhou Y, Yu Y, Zhou X, Du W, Wan M, Fan Y, Zhou X, Xu X, Zheng L (2019) Evaluation of
13 Chitosan Hydrogel for Sustained Delivery of VEGF for Odontogenic Differentiation of Dental Pulp
14 Stem Cells. *Stem Cells Int.* **2019**. doi:10.1155/2019/1515040.

15
16 Xiao N, Thor D, Yu WY (2020) Neurotrophins BDNF and NT4/5 accelerate dental pulp stem
17 cell migration. *Biomed. J.:* 2–7. doi:10.1016/j.bj.2020.03.010.
18 <https://doi.org/10.1016/j.bj.2020.03.010>.

19
20 Xiao N, Yu WY, Liu D (2018) Glial cell-derived neurotrophic factor promotes dental pulp stem
21 cell migration. *J. Tissue Eng. Regen. Med.* **12**: 705–714. doi:10.1002/term.2490.

22
23 Xu Q, Zhang Q, Ishida Y, Hajjar S, Tang X, Shi H, Dang C V., Le AD (2017) EGF induces
24 epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via
25 promoting Warburg effect. *Oncotarget* **8**: 9557–9571. doi:10.18632/oncotarget.13771.

26
27 Yang X, Van Der Kraan PM, Bian Z, Fan M, Walboomers XF, Jansen JA (2009) Mineralized
28 tissue formation by BMP2-transfected pulp stem cells. *J. Dent. Res.* **88**: 1020–1025.
29 doi:10.1177/0022034509346258.

30
31 Yang X, Han G, Pang X, Fan M (2012) Chitosan/collagen scaffold containing bone
32 morphogenetic protein-7 DNA supports dental pulp stem cell differentiation in vitro and in vivo. *J.*
33 *Biomed. Mater. Res. - Part A:* 1–8. doi:10.1002/jbm.a.34064.

34
35 Ye L, Peng L, Tan H, Zhou X (2006) HGF Enhanced Proliferation and Differentiation of Dental
36 Pulp Cells. *J. Endod.* **32**: 736–741. doi:10.1016/j.joen.2006.01.007.

37
38 Youssef AR, Emara R, Taher MM, Al-Allaf FA, Almalki M, Almasri MA, Siddiqui SS (2019)
39 Effects of mineral trioxide aggregate, calcium hydroxide, biodentine and Emdogain on osteogenesis,
40 Odontogenesis, angiogenesis and cell viability of dental pulp stem cells. *BMC Oral Health* **19**: 1–9.
41 doi:10.1186/s12903-019-0827-0.

42
43 Zafar K, Jamal S, Ghafoor R (2020) Bio-active cements-mineral trioxide aggregate based
44 calcium silicate materials: A narrative review. *J. Pak. Med. Assoc.* **70**: 497–504.
45 doi:10.5455/JPMA.16942.

46
47 Zhang J, Lian M, Cao P, Bao G, Xu G, Sun Y, Wang L, Chen J, Wang Y, Feng G, Cui Z (2017a)
48 Effects of Nerve Growth Factor and Basic Fibroblast Growth Factor Promote Human Dental Pulp
49 Stem Cells to Neural Differentiation. *Neurochem. Res.* **42**: 1015–1025. doi:10.1007/s11064-016-
50 2134-3.

51
52 Zhang M, Jiang F, Zhang X, Wang S, Jin Y, Zhang W, Jiang X (2017b) The Effects of Platelet-
53 Derived Growth Factor-BB on Human Dental Pulp Stem Cells Mediated Dentin-Pulp Complex
54 Regeneration. *Stem Cells Transl. Med.* **6**: 2126–2134. doi:10.1002/sctm.17-0033.

55
56 Zhang R, Cooper PR, Smith G, Nör JE, Smith AJ (2011) Angiogenic activity of dentin matrix
57 components. *J. Endod.* **37**: 26–30. doi:10.1016/j.joen.2010.08.042.

58
59 Zhang W, Walboomers XF, Jansen JA (2008) The formation of tertiary dentin after pulp
60 capping with a calcium phosphate cement, loaded with PLGA microparticles containing TGF- β 1. *J.*

1
2
3 Biomed. Mater. Res. - Part A **85**: 439–444. doi:10.1002/jbm.a.31558.
4

5 Zhang W, Liu W, Ling J, Lin Z, Gao Y, Mao X, Jian Y (2014) Odontogenic differentiation of
6 vascular endothelial growth factor-transfected human dental pulp stem cells in vitro. Mol. Med. Rep.
7 **10**: 1899–1906. doi:10.3892/mmr.2014.2481.
8

9 Zhao S, Sloan AJ, Murray PE, Lumley PJ, Smith AJ (2000) Ultrastructural localisation of TGF- β
10 exposure in dentine by chemical treatment. Histochem. J. **32**: 489–494.
11 doi:10.1023/A:1004100518245. <https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033766851&doi=10.1023%2FA%3A1004100518245&partnerID=40&md5=f834fe33efdf6b8288f549107180f2ac>.
12
13
14

15 Zhu C, Ju B, Ni R (2015) Clinical outcome of direct pulp capping with MTA or calcium
16 hydroxide: A systematic review and meta-analysis. Int. J. Clin. Exp. Med. **8**: 17055–17060.
17 <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L607200947>.
18

19 Zhu L, Ma J, Mu R, Zhu R, Chen F, Wei X, Shi X, Zang S, Jin L (2018) Bone morphogenetic
20 protein 7 promotes odontogenic differentiation of dental pulp stem cells in vitro. Life Sci. **202**: 175–
21 181. doi:10.1016/j.lfs.2018.03.026. <https://doi.org/10.1016/j.lfs.2018.03.026>.
22

23 Zhu Q, Gao J, Tian G, Tang Z, Tan Y (2017) Adrenomedullin promotes the odontogenic
24 differentiation of dental pulp stem cells through CREB/BMP2 signaling pathway. Acta Biochim.
25 Biophys. Sin. (Shanghai). **49**: 609–616. doi:10.1093/abbs/gmx053.
26

27 Zhu Q, Tian G, Tang Z, Gao J, Tan Y (2016) Adrenomedullin Promotes the Proliferation and
28 Inhibits Apoptosis of Dental Pulp Stem Cells Involved in Divergence Pathways. J. Endod. **42**: 1347–
29 1354. doi:10.1016/j.joen.2016.06.001. <http://dx.doi.org/10.1016/j.joen.2016.06.001>.
30

31 Zohrabian VM, Poon CS, Abrahams JJ (2015) Embryology and Anatomy of the Jaw and
32 Dentition. Semin. Ultrasound, CT MRI **36**: 397–406. doi:10.1053/j.sult.2015.08.002.
33 <http://dx.doi.org/10.1053/j.sult.2015.08.002>.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60